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~    Approximately 
˚C  Degrees Celsius 
%    Percentage 
ABL       Abelson Murine Leukaemia 
ADME        Absorption, Distribution, Metabolism and Excretion 
APC        Adenomatous polyposis coli 
BCA        Bicinchonic Acid 
BCl-2      B-cell lymphoma-2
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Compound 53  C53 
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ER       Estrogen Receptor 
EGFR       Epidermal Growth Factor Receptor 
EC50        Half maximal effective concentration 
FBS       Fetal Bovine Serum 
FDT        Free Drug Theory 
Fu       Free fraction 
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GI                                                       Gastrointestinal 
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The Karyopherin superfamily is a group of soluble transport proteins which are involved in 
nuclear-cytoplasmic trafficking. Studies have shown the involvement of Karyopherin proteins 
in nuclear pore assembly, nuclear membrane assembly and DNA replication. Since all these 
cell regulatory functions are critical for normal cell function, dysregulation of Karyopherin 
proteins may have an impact on cancer cell survival. Previous research in our laboratory and 
in that of others has shown that Karyopherin Beta 1 (KPNB1) is elevated in and necessary for 
the survival of cervical cancer cells as inhibiting its expression with siRNAs interfered with the 
proliferation of cancer cells. KPNB1 has thus been proposed as an anticancer target. In 
addition to inhibition by siRNA, an in silico screen for small molecules with potential to bind 
KPNB1 identified a number of compounds that are currently under investigation for their 
cancer cell killing effects. In this study, we investigated the ability of a novel small molecule 
1-benzyl-4[(4-methoxy-1-naphyl) methylamino]-N-methyl pyrrolidine-2-carboxamide 
(Compound 53) to kill cancer cells and inhibit the activity of KPNB1 cargo proteins. In addition, 
the in vitro pharmacokinetic properties and in vivo toxicology of Compound 53 (C53) were 
investigated.  
Cervical (HeLa and CaSki) and oesophageal (WHCO6 and Kyse30) cancer cell lines were found 
to be more sensitive to C53 treatment compared to non-cancer cells (FG0), with EC50 values 
of ~ 20 µM for the cancer cell lines and ~ 30-40 µM for the non-cancer cells. C53 treatment 
significantly inhibited proliferation in cancer cell lines. The reduction in proliferation in cancer 
cells was associated with a block in the G1 phase of the cell cycle and a change in the 
expression of cell cycle related proteins such as CyclinD1 and CDK4. C53 treatment resulted 
in cell death via apoptosis as observed using Annexin V staining and PARP cleavage.   
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To assess whether C53 interferes with KPNB1 associated nuclear import, we investigated the 
effect of C53 on the activity of KPNB1 cargo proteins, NFAT and NF-ĸB as well as investigate 
its effect on KPNB1 localisation. The results show that C53 has no effect on the localisation of 
KPNB1 but it does however block the nuclear activity of the KPNB1 cargoes, NFAT and NF-ĸB. 
In order to predict the behaviour of C53 in a living system, in vitro ADME pharmacokinetic 
studies showed that C53 has moderate solubility, permeability and protein binding however, 
rapid clearance was shown by liver microsome assay. In vivo repeated dose toxicology studies 
showed that C53 is tolerable in nude mice.  
Taken together, the data presented in this study shows that a novel small molecule, C53 has 
a negative effect on the proliferation of cancer cells, inhibits the nuclear import of KPNB1 
cargoes, displays tolerable in vitro ADME pharmacokinetic properties and showed no toxic 
side effects in vivo. These results suggest that C53 targets KPNB1 and shows potential as an 
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Surgery and radiation are still the most common methods used to remove cancer cells from 
the body. These methods are specifically used for localised tumours which have not 
metastasised, and therefore can be removed surgically or directly killed by high radiation e.g. 
localised breast cancer and prostate cancer tumours [5,6]. Chemotherapy is also a common 
method used to treat cancer and involves administering drugs which target rapidly dividing 
cells. Chemotherapy not only kills rapidly dividing cancer cells but also kills rapidly dividing 
normal cells which leads to side effects such as vomiting, hair loss and mouth sores [4]. The 
side effects associated with chemotherapies are largely thought to be due to the off-target 
effects of chemotherapy. To try and minimize off target effects, recent research strategies 
include investigations focussed on targeted therapies.  
 
1.3 Targeted therapy as an anticancer approach 
Targeted therapy is a class of cancer therapy designed to specifically interfere with molecular 
targets which have been shown to be essential for tumour growth. With the increasing 
knowledge of molecular events underlying human cancer, the ability to target specific genes 
or proteins which are essential for cancer cell survival has become possible [7]. Unlike 
conventional chemotherapeutic approaches which mainly target rapidly dividing cells, 
targeted therapy homes in on characteristics that are essential for cancer progression [4]. An 
example of a drug with a specific target is Tamoxifen which was approved in the 1970s. 
Tamoxifen is a therapy used for the treatment of breast cancer and functions by binding to 
the Estrogen Receptor (ER) which in turn inhibits estrogen from binding the ER. By interfering 
with the binding of estrogen, Tamoxifen can modulate the ER activity in patients with ER-
positive breast cancer [7].  






  1.1 Cancer 
Cancer is a group of diseases characterised by the abnormal growth of cells which have the 
potential to invade and spread to other parts of the body. Worldwide cancer is one of the 
leading causes of mortality with approximately 14 million new cases recorded in 2012. In 
2012, approximately 8.8 million deaths in low and middle-income countries was attributed to 
cancer [1]. Even though there has been substantial progress regarding cancer prevention and 
treatment, the global cancer burden continues to rise due to a growing and aging population 
as well as increasing risk factors such as smoking, unhealthy food choices and obesity [2]. 
These statistics highlight the necessity for early detection methods and developing better 
treatments for cancer.  
 
1.2 Current cancer treatments 
Cancer development is a multistep process generally involving genetic mutations which in 
turn drive the transformation of normal cells. Recent advances in genomic, proteomic and 
bioinformatic technologies are revealing the complexity of the genetic interplay involved in 
cancer progression which has made treatment of cancer very difficult [3]. Clinicians have 
access to a number of approaches to treat cancer including surgery, chemotherapy, 
immunotherapy, radiation, target therapy and hormone therapy. Based on the type of cancer, 
one or a combination of these treatment methods can be used [4].  
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The discovery of tumour suppressor genes and oncogenes has resulted in improving the 
understanding of cancer development, which has allowed the introduction of more cancer 
target therapies [7]. Examples of these include a series of receptor proteins and protein 
kinases that have been shown to be mutated or overexpressed in human cancer. These 
include the Epidermal Growth Factor Receptor (EGFR), Insulin Growth Factor (IGF) receptors, 
Human Epidermal growth factor Receptor 2 (HER2), Abelson Murine Leukemia (ABL) and 
MAPK/ ERK Kinase (MEK) [7]. The inactivation of several of these kinases with target specific 
inhibitors have shown positive clinical results in patients with cancer and have been FDA 
approved to treat various cancers [7,8]. Examples of FDA approved tyrosine kinase inhibitors 
include Lapatinib a HER2 inhibitor used to treat breast cancer, Nilotinib an ABL inhibitor used 
to treat chronic myelogenous leukemia, Gefitinib an EGRF inhibitors used to treat non-small 
cell lung cancer. The successes of some of these target therapy drugs illustrates the power of 
this approach and shows the need for further investigation into the molecular studies of 
human cancers [8]. 
 
1.3.1 Types of target therapies  
The aim of target therapy is to reduce or block the growth and spread of cancer cells by 
interfering with a specific target that cancer cells are highly reliant on [9]. Target therapies 
include small molecule inhibitors and monoclonal antibodies. Small molecule inhibitors are 
low molecular weight chemical agents that are designed to target specific cellular proteins. 
Monoclonal antibodies, which are large, generally do not enter the cell therefore target 
proteins on the cell surface or outside of the cells [10].  
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Many different target therapies have been used for cancer treatment. Some of the types of 
target therapy include signal transduction inhibitors, gene expression modulators, apoptosis 
inducers and angiogenesis inhibitors. Signal transduction refers to the process of 
communication used by regulatory molecules to control essential cell processes such as 
differentiation, growth and survival. Alteration in signal transduction components may lead 
to increased proliferation, sustained angiogenesis and tissue invasion which is the case in 
most human cancers [11].  Some commercially available compounds which target altered 
signal transduction elements such as tyrosine kinases include Gefitinib, an inhibitor of the 
ErbB-1 receptor kinase used to treat non-small cell lung cancer and Trastuzumab, an antibody 
used to target the HER- 2 receptor to treat HER- 2 positive breast cancer [11]. 
Gene expression modulators are target therapy agents that modify the function of proteins 
which are involved in controlling gene expression. In cancer, this is specifically important as 
cancer is associated with abnormal gene mutations and gene expression patterns [12]. Many 
gene expression modulators trigger cell death by apoptosis. Apoptosis is a tightly regulated 
form of cell death which maintains the healthy survival of cells. Defects in apoptosis has been 
shown to lead to cancer and autoimmunity [13]. Cancer cells can use mechanisms to suppress 
apoptosis and in turn become resistant to apoptotic agents. Therefore, the development of 
apoptotic inducers for cancer cells is an approach to target the antiapoptotic mechanisms in 
cancer [13]. Examples of drugs which induce apoptosis include AT-101 and ABT-263 which are 
currently undergoing clinical trials. These drugs target the antiapoptotic B-cell lymphoma-2 
(BCl-2) family of proteins which in turn leads to the induction of apoptosis [14].  
Angiogenesis refers to the production of blood vessels. This process is essential to provide 
tumours with oxygen and nutrients which allows for their growth. Angiogenesis may be an 
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important contributor to tumour progression, invasion and metastasis. An example of a 
growth factor secreted by tumour cells is the Vascular Endothelial Growth Factor (VEGF) 
which is a pro-angiogenic factor mediates blood vessel formation [15]. Targeting angiogenesis 
has led to the development of several commercially available compounds such as neutralizing 
antibodies Bevacizumab and Ramucirumab as well as some tyrosine kinase inhibitors which 
also target angiogenesis (Sunitinib and Sorafenib) [15].  
 Different target therapies thus target different molecules with the aim to reduce the spread 
of cancer.  The above examples are commercially available compounds that target a variety 
of cancer dependent targets. The success of these compounds provides a platform for further 
development of new target therapy compounds with the hope of targeting cancer specific 
characteristics with reduced off-target effects. 
1.3.2 Identification of cancer targets 
The advancement of genomics, sequencing and high throughput technology has made it 
possible to understand diseases better but also identify potential gene targets which could 
be used in targeted therapy [16]. Previous work done in our laboratory used cDNA microarray 
analysis to profile the gene expression patterns of normal and cervical cancer tissue to 
identify specific genes that associate with cervical cancer [17]. Numerous genes with 
differential expression in cervical cancer tissue were identified and amongst these, multiple 
members of the nuclear transport family of proteins were shown to be overexpressed in 
cervical cancer tissues in comparison to normal tissues. These proteins belong to the 
Karyopherin super family which function in the shuttling of macromolecules between the 
nucleus and cytoplasm [17].  
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1.4 Nuclear cytoplasmic transport is an essential cellular function 
In eukaryotic cells, a double membrane known as the nuclear envelope separates the nucleus 
from the cytoplasm. Due to this spatial segregation, efficient mechanisms of transport are 
required to transport macromolecules across the nuclear envelope which allows for a level of 
regulation which does not exist in prokaryotic cells [18]. Processes such as DNA and RNA 
synthesis occur in the nucleus while protein synthesis occurs in the cytoplasm. For these 
cellular processes to work together selective transport of proteins and ribonucleoproteins 
between the nucleus and cytoplasm is required. This process is known as the nuclear 
cytoplasmic transport. Large macromolecules are transported through large protein 
complexes, which cross the nuclear envelope, known as Nuclear Pore Complexes (NPCs) [18]. 
The NPC is a highly selective ‘channel’ which allows entry into and out of the nucleus and 
regulates the transport of macromolecules [19]. The function of the NPC is to prevent the 
transport of nonspecific macromolecules, yet allow the diffusion of water, sugars and ions. In 
addition to its role in nuclear transport research has shown that the NPC play a role in gene 
expression regulation.  It has been shown that the regulation in gene expression can be 
achieved by modulating the transcription factors involved in nuclear cytoplasmic transport or 
by regulating epigenetic enzymes [20,21]. The NPC is also able to regulate gene expression by 
controlling the proportion of transcription factors in the nucleus and cytoplasm, for example 
NF-ĸB accumulation in the nucleus is determined, in part, by Nucleoporin 88 (Nup88) [22]. 
Defects in the NPC have been implicated in different human pathologies such as cancer, viral 
infections and cardiovascular pathologies [23].   
Other cellular components critical for nuclear transport include the nucleo/cytoplasmic 
machinery e.g Karyopherin proteins and Ran. See section 1.5 for discussion of these.  
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1.4.1 Nuclear cytoplasmic transport is altered in cancer  
Nuclear cytoplasmic transport is a tightly regulated process which involves the import or 
export of cargo between the nucleus and cytoplasm. There is evidence in the literature that 
nuclear cytoplasmic transport pathways are altered in cancer cells. Defects in the nuclear 
cytoplasmic transport process have been detected in several human cancers including breast, 
cervical, colorectal and ovarian cancers [24]. These defects have been shown to occur in the 
general nuclear cytoplasmic transport machinery or in signal transduction pathways via the 
mislocalisation of transcription factors [24]. Since the cellular localisation of protein is crucial 
for normal cell function, cancer cells are thought to utilize this process of nuclear cytoplasmic 
transport via the NPC to evade anticancer mechanisms [25]. It is no surprise that disruption 
of nuclear cytoplasmic transport associates with oncogenesis since subcellular localisation of 
proteins is of such importance for cellular function [26]. Regulated transportation of protein 
ensures that the correct amount of protein is present at the right place at the right time. 
Therefore, mislocalisation of protein or transcription factors can lead to loss of function or 
harmful toxic activity at the wrong place. The transcription factor forkhead box O3a (FOXO3a) 
is an example of a tumour suppressor whose function is dependent on localisation. 
Cytoplasmic localisation of this transcription factor has been correlated with poor survival in 
breast cancer while nuclear localisation correlates with increased sensitivity to radiation [27]. 
Several oncogenes and tumour suppressors are often mislocalised in cancer e.g. p53, β-
Catenin, Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB), Nuclear 
Factor of activated T cells (NFAT) and Hypoxia-inducible factor alpha (HIF-α) (Table 1). Other 
proteins such as p27, Adenomatous polyposis coli (APC) and Rb, which play an important role 
in preventing cancer initiation and progression, have also been reported to be mislocalised in 
cancer [26].  
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Table 1: Proteins which have been shown to be mislocalised in different human cancers 
[26]. 





Various cancers Nucleus Cytoplasm 
Β-Catenin Win signalling Colorectal cancer Cytoplasm Nucleus 
p53 Transcriptional 
factor 
Various cancers Nucleus Cytoplasm 
Galectin-3 Beta-galactoside-BP Various cancers Nucleus Cytoplasm 
BARD1 BRAC1 interacting 
protein 
Breast cancer Cytoplasm Nucleus 
BRAC1 DNA repair Breast cancer Cytoplasm Nucleus 
NF-ĸB Transcription factor Various cancers Cytoplasm Nucleus 
NPM1 Ribonucleoprotein AML Nucleus Cytoplasm 
p21WAF1 Cell cycle inhibitor CML, ovarian, 
breast 
Nucleus Cytoplasm 
p27KIP  Cell cycle inhibitor AML, breast Nucleus Cytoplasm 
RUNX3 Transcription factor Gastric cancer Nucleus Cytoplasm 
INI1 Tumour suppressor Rhabdoid tumours Nucleus Cytoplasm 
RB E2F BP Various cancers Nucleus Cytoplasm 
HIF-1α Transcription factor Breast, prostate 
cancer 
Cytoplasm Nucleus 
NFAT Transcription factor Various cancers Nuc/Cyt Nucleus 
PTEN Phosphatase  Various cancers Nuc/Cyt Cytoplasm 
Bcr-Abl Kinase CML Nuc/Cyt Cytoplasm 
Fbw7γ Ubiquitin ligase Various cancers Nucleus Not nuclear 
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Some of the proteins that have been shown to be mislocalised are also implicated in different 
human cancers. For example, the NF-ĸB signalling pathway has been shown to play a role in 
cancer initiation and progression while p53 has been reported to be mutated in several 
human cancers [28,29]. 
Other than the mislocalisation of proteins, defects in the general machinery of the nuclear 
cytoplasmic transport process have also been observed in human cancers. These defects 
include the overexpression of certain transport machinery e.g. CRM1, Cas and KPNα as well 
as KPNB1 [17,30]. A research focus in our laboratory has an interest on KPNB1 expression and 
activity in cancer cells. 
 
1.5 Karyopherin B1 (KPNB1) mediated nuclear-cytoplasmic transport 
1.5.1 Nuclear-cytoplasmic transport 
The trafficking of cargo between nuclear and cytoplasmic compartments is essential for 
proper cellular function [31]. There are two main mechanisms of translocation across the 
nuclear envelope, (i) passive and (ii) active transport. Passive transport refers to a diffusion-
based process which is dependent on Brownian motion via the central pore. This process is 
limited to molecules that fall below the size range of 40 to 60 KDa [31]. Active transport, also 
known as facilitated transport, is dependent on proteins which facilitate transport such as 
Karyopherin proteins. The transport of cargoes occurs via the nuclear pore complex which 
acts as a passage for translocation into and out of the nucleus [32]. This form of transport is 
specific to larger molecules such as transcription factors, enzymes, nuclear receptors, RNA 
and proteins [32]. Active transport requires the presence of translocation signals known as 
the nuclear localisation or nuclear export signals which are found on the proteins that require 
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translocation across the nuclear envelope. The Nuclear Localisation Signal (NLS) acts as 
recognition signals which can be recognized by a special family of transport receptors such as 
the Karyopherins [32]. 
1.5.2 Karyopherin proteins as nuclear transport proteins 
The Karyopherin super family consists of a series of transport receptors which play a role in 
transporting proteins in and out of the nucleus via the nuclear pore complex. The nuclear 
transport protein responsible for shuttling protein and RNA into the nucleus are known as 
Importins while the nuclear receptors that shuttle protein and RNA out of the nucleus are 
known as Exportins [32]. Although there are a variety of NLSs and Karyopherins with different 
cargo preferences, the classical nuclear import pathway recognizes a specific lysine-rich 
classical Nuclear Localisation Signal (cNLS) which initiates the pathway (Figure 1.1). The lysine-
rich cNLS is recognized by Karyopherin-α (KPNα) which is an adaptor importin specialised in 
cNLS recognition [31]. Once KPNα binds the cargo via the cNLS, Karyopherin-B1 (KPNB1) 
import protein, binds KPNα forming a trimeric complex. A Ras-relate small guanosine 
diphosphatase known as RanGDP binds the importin and provides energy for nuclear import 
allowing the trimeric complex to enter the nucleus. In the nucleus the RanGDP bound to 
KPNB1-Kpnα-cargo complex gets converted to RanGTP by a GTPase enzyme known as RanGAP 
which causes the dissociation of the cargo [33]. The RanGTP bound KPNB1-KPNα complex 
then translocates back into the cytoplasm where RanGTP is hydrolysed into RanGDP in the 
cytoplasm for another round of nuclear import [34]. The non-classical import pathway is 
another KPNB1 dependent import pathway. In the non-classical nuclear import pathway, the 
NLS of certain cargoes e.g. Histones and Ribosomal proteins are directly recognized by KPNB1 
which then binds the cargo. The KPNB1-cargo complex then translocates into the nucleus via 
the NPC and upon binding to the RanGTP the cargo is released [35].  





Figure 1.1. A representative image of the KPNB1 dependent nuclear import pathway. In the 
Non-classical import pathway (Left), KPNB1 binds the cargo and transports it into the nucleus 
via the NPC. In the nucleus Ran-GTP binds to KPNB1 which causes the cargo to dissociate. In 
the Classical import pathway (Right), an adaptor protein (KPNα) binds the cargo which then 
causes the binding of KPNB1 forming a trimeric complex (Right). The trimeric complex then 
enters the nucleus and associates with Ran-GTP to dissociate the cargo [35].  
 
Although Karyopherin B1 mediates the nuclear import of a large amount of proteins, several 
Karyopherin B-like importins namely, Importin 2,3,4,5,7,8,9,11,12 and 13 have been 
identified all of which play a role in importing various proteins into the nucleus. These 
Karyopherin B-like proteins have similar molecular weights (95-145 KDa) and contain helical 
HEAT repeats [36]. Table 1 lists the different human importins and their respective cargoes.  
Interestingly, Importin 7 has the highest identified cargoes and in some cases Importin 7 has 
been shown to act in complex with Importin-B. Like KPNB1, these importins also recognize 
specific NLS on proteins. For example, Importin-B2 recognizes diverse sequences called PY-
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NLS. There are over 100 human proteins with the PY-NLS which are recognized by Importin-
B2 [37]  
Table 1: List of Karyopherin B-like importins and their respective cargoes [37]. 
Importins  Examples of cargoes transported 
Importin 2 c-Jun, ribosomal protein, c-Fos 
Importin 3 HuR, hnRNP A1 
Importin 4 HIF1-α, Vitamin D receptor 
Importin 5 c-Jun, ribosomal protein 
Importin 7 ERK1/2, MEK1, SMAD3/4, c-Jun, HIF1-α, GR, Sox-
2 
Importin 8 SMAD1/3/4, glucocorticoid receptor 
Importin 9 Sox-2, c-Jun, ARX 
Importin 11 UbcH6, UB2E2 
Importin 12 MLF2, RBM4 
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Some of the transport receptors in the nuclear cytoplasmic transport pathway have been 
implicated in different human cancers. For example, CRM1 which is an export protein has 
been shown to be over expressed in cervical, ovarian, pancreatic cancer [17,39,40] and 
implicated in poor patient survival while the adaptor protein KPNα is overexpressed in 
ovarian, breast, cervical cancer and linked to short disease- free survival [17,41,42]. Unlike 
CRM1 and KPNα, there are limited studies of the link of KPNB1 and human cancers. Research 
in our laboratory has shown elevated expression of KPNB1 in cervical cancer cell lines and 
patient tissues in comparison to non-cancer cells [43]. Research by Kuuisto et al. has shown 
elevated expression of KPNB1 in breast cancer cell lines [44]. Research has also shown 
elevated expression of KPNB1 in bladder and gastric cancer [45,46]. The increasing evidence 
of KPNB1 being overexpressed in various cancer suggests its potential as a target for target 
therapy.  
1.5.3 KPNB1 as a target for cancer therapy 
KPNB1 has been shown to have function in nuclear transport as well as regulate mitosis and 
other cell regulatory functions such as nuclear pore assembly, nuclear membrane assembly 
and DNA replication in the S phase [47]. Since KPNB1 is involved in nuclear import as well as 
different non-transport cellular processes it is essential that its expression is tightly regulated 
to maintain cellular homeostasis.  
Studies have shown that elevated expression of KPNB1 may correlate to increased nuclear 
import and export efficiency [48]. This increased transport efficiency has been suggested as a 
possible mechanism for cancer cells to cope with increased proliferative and metabolic 
demands. Using bioinformatic and molecular biology approaches research in our laboratory 
showed that the overexpression of KPNB1 observed was due to the dysregulation of E2F/Rb 
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activity in cervical cancer cells [17]. When KPNB1 expression was inhibited using siRNA, cell 
death in cervical cancer cells was observed with minimal effects on non-cancer cells [48]. 
Elevated expression of KPNB1 has also been shown in breast cancer cells where suppression 
of KPNB1 by siRNA resulted in reduced proliferation of breast cancer cells [49]. Recent 
research has identified KPNB1 as a possible target for lung adenocarcinoma treatment. This 
research showed that Polo like Kinase 1 (PLK1) inhibition lead to reduced expression of KPNB1 
where reduced expression lead to a reduction in cancer cell proliferation via apoptosis [50]. 
The increased expression and reliance of cancer cells on KPNB1 in comparison to non-cancer 
cells suggests it has potential as an anticancer target. 
1.5.4 KPNB1 Structure 
The KPNB proteins have been reported to vary in size between 90 KDa and 130 KDa. KPNB1 
is composed of 19 helical motifs commonly known as HEAT repeats. The HEAT repeats are 
each approximately 40 residues long. The main repeat unit consists of a hairpin made up of 2 
B- helices known as helix A and helix B which are separated by a sharp turn (Figure 1.2). One 
turn forms a long acidic loop at HEAT 8 which is critical for the regulation of substrate binding 
and release during translocation [51].  
 
 
Figure 1.2. KPNB1 containing 19 HEAT repeats. Helix A and B are connected by a sharp acidic 
loop at HEAT 8 which essential for substrate binding and release. HEAT repeat 1-8 are 
required for RanGTP binding while HEAT 7-19 are required for KPNα binding. HEAT repeat 4-
8 are required for binding nucleoporins during nuclear import [51]. 
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Since KPNB1 plays a role in classical nuclear import via the interaction of KPNα and RanGTP, 
these proteins should have specific binding regions on KPNB1. Crystal structure analysis 
revealed that RanGTP binds KPNB1 via the amino-terminal domain while cargo binds via the 
carboxyl domain. The full length KPNB1 complexed with the binding domain of KPNα was 
shown to form a snail-like super helix in which the C- and N-terminal HEAT repeats were near 
[52]. The RanGTP bound form of KPNB related protein KPNB2 forms an S-like twisted right 
handed helix [53]. Knowing the regions of KPNB1 required for its function e.g the KPNα and 
Ran binding domain, allows for the investigation into molecules that may target these regions. 
In identifying targeted therapies, structure-based approaches can be used.  
 
1.6. Identification of small molecule inhibitors in drug discovery 
The main aim of targeted therapy is to identify small molecule inhibitors or antibodies which 
selectively bind a target which cancer cells are highly dependent on [9]. While previous 
studies have shown that cancer cells are dependent on KPNB1 for their survival, few inhibitors 
that target KPNB1 as an anticancer approach have been identified. Research aimed at 
identifying small molecule inhibitors against KPNB1 presents a novel anticancer approach.  
The process of drug discovery utilizes different modelling methods to study chemical and 
biological systems [54]. The use of computational and experimental methods has been of 
value in the identification of novel therapeutic compounds. Structure based drug design 
methods is a prominent method in drug discovery which uses the 3-D structural information 
gathered from the protein [54].  
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1.6.1 Structure based drug design (SBDD) and molecular docking of chemical compounds  
In the process of drug discovery and design, understanding the fundamentals of how small 
molecule ligands recognize and interact with macromolecules is crucial in identifying novel 
compounds. Structure based drug design (SBDD) refers to the use of structural data, usually 
obtained experimentally or through computational modelling, to design/identify chemical 
compounds which bind a specific target [55]. The purpose of SBDD is to identify ligands with 
specific stereochemical and electrostatic attributes allowing for strong binding to the 
receptor of interest. The process of SBDD is a cyclic process which starts with a known target 
structure which is identified through in silico studies. After molecular modelling of the target 
and potential compounds, synthesis of the most promising compounds takes place. Next the 
compounds are tested for their biological activities to obtain relevant biological information 
(potency, activity, efficacy). Once biological information is collected the SBDD process starts 
again with new steps to incorporate molecular modifications to improve binding affinity of 
chosen compound [56].  
Molecular docking is a common method used in SBDD due to its ability to predict the 
conformation of small-molecule ligands within the appropriate binding site of the receptor of 
interest. The first molecular docking algorithm was developed in the 1980s and since then, 
molecular modelling has become an essential tool in drug discovery [56].  
The docking process requires a 3-D structure of the ligand and the receptor. The 
ligand/compound is docked into the binding site and different conformations are explored 
until the most likely binding conformation is identified. The process is carried out until 
convergence to the conformation with minimum energy [56]. 
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1.6.2 Pharmacology in drug design  
Rational drug design assumes a simple relationship between exposure of a drug and its 
therapeutic effect. However, since living system are far more complex the relationship is not 
that straight forward. Many failures of drug candidates in drug development is due to 
undesirable pharmacokinetic properties such as short half-life (t1/2), poor absorption or 
excessive metabolism. The failure rate of many drug candidates illustrates the importance of 
incorporating pharmacokinetics in drug discovery and development [57].  
Pharmacokinetics can be defined as the study of a drug’s movement in the body. This can be 
investigated through Absorption, Distribution, Metabolism and Excretion (ADME). Research 
has shown that the initiation of early pharmacokinetic screening in the form of ADME in vitro 
and in vivo screening has decreased the proportion of compounds failing in clinical trials. The 
aim of ADME screening is to eliminate or improve drug candidates in the early stages of drug 
development [57]. In vitro ADME screening uses different assays to investigate specific 
characteristics of a compound which will affect the absorption, distribution, metabolism and 
excretion in a living system. Absorption refers to how a drug will be taken up into the blood 
which is usually affected by the permeability and lipophilicity of a compound. Distribution 
refers to how a drug will be transported which usually is via the blood hence the solubility of 
a drug is important. Metabolism refers to how a compound is broken down by metabolising 
enzymes to form metabolites. This has important implications for the clearance of a drug but 
also allows for the identification of specific metabolites which could be more active then the 
parent drug [57,58].  Lastly, Excretion refers to how the compound will by excreted from the 
system. Investigating properties such as solubility, plasma protein binding, lipophilicity, 
permeability and metabolic stability is important in providing crucial pharmacokinetic data 
which can guide future animal and clinical studies [58]. Therefore, the incorporation of 
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pharmacokinetics in drug discovery of small molecule inhibitors in the early stages of drug 
development will allow for better understanding of how these compounds may act in a living 
system.  
 
1.7 Inhibitors of nuclear transport  
KPNB1 plays an important role in nuclear cytoplasmic transport by acting as a transport 
protein which imports various cargo selectively. The elevated expression of KPNB1 has been 
implicated in various human cancers which has made it a target of interest for cancer therapy. 
Since normal cells seem to be less reliant on KPNB1 for their survival as opposed to cancer 
cells this makes KPNB1 a potential for target therapy [17]. 
Drugs which target KPNB1 are still limited. The first KPNB1 targeting small molecule inhibitor 
to be identified was Karyostatin 1A. Karyostatin 1A was shown to bind KPNB1 with high 
affinity and specifically targeted the classical import pathway in vitro and in vivo. Although 
Karyostatin 1A showed anticancer activity, its off-target effects have not been investigated 
[59]. Other inhibitors such as peptide inhibitors and small molecule peptidomimetic inhibitors 
of the classical import pathway have been used to study nuclear import in vivo however, these 
inhibitors were not successful as they are not cell permeable [60].  
Importazole, a 2,4-diaminoquinazoline is currently the only commercially available small 
molecule inhibitor of KPNB1 which has been reported [60]. Therefore, future investigation 
and identification of additional small molecule inhibitors of KPNB1 could provide novel 
therapeutics for cancer treatment. 
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1.7.1 Identification of small molecules with inhibitory activity against KPNB1 function 
Previous work in our laboratory aimed at identifying potential KPNB1 inhibitors. A structure-
based computational screen was performed in collaboration with the Molecular Modelling 
Facility of the James Graham Brown Centre at the University of Louisville, Kentucky, USA. An 
in silico screen for small molecules with potential to bind KPNB1 was performed using the 
known crystal structure of KPNB1. The region of KPNB1 targeted included the overlapping 
RanGTP and KPNα binding sites of KPNB1. This RanGTP and KPNα overlapping region has been 
shown to be essential for KPNB1 mediated nuclear transport [51]. A library of drug-like 
compounds was screened against the target site and ranked according to their potential 
KPNB1-binding affinity. Forty-seven of the highest ranked compounds were then screened in 
cell culture studies for their ability to block nuclear import and their effect on cancer cell 
viability. Several compounds were identified of which Inhibitor of Nuclear Import 43 (INI-43), 
Compound 53 (C53) and Compound 60 (C60) were selected from 16 compounds which had 
cell killing activity at ≤ 50 µM, a concentration in the range of that of current 
chemotherapeutics tested on cervical cancer cell lines in culture [62]. Our lab has done 
extensive studies on INI-43 which showed anticancer activity as well as inhibition of KPNB1 
[62]. The focus of this MSc study is to investigate C53 as a novel compound with anticancer 
activity and its potential to inhibit KPNB1 associated nuclear import. 
1.7.2 C53 as a potential KPNB1 small molecule inhibitor 
C53, chemically known as 1-benzyl-4[(4-methoxy-1-naphyl) methylamino]-N-methyl-
pyrrolidine-2-carboxamide is a pyrrolidine derivative (Figure 1.3). Interestingly, studies have 
shown that pyrrolidine has anticancer activities and acts as an inhibitor of Matrix 
metalloproteinases 2 and 9 which have been reported to have a key role in tumour growth, 
   
33 
 
invasion and metastasis in cancer tissues [63]. Our study aims to further investigate and 

























Figure 1.3 Chemical structure of C53 (1-benzyl-4[(4-methoxy-1-naphyl) methylamino]-N-
methyl-pyrrolidine-2-carboxamide) 
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1.8 Significance of the study 
Recent work suggests that KPNB1 is overexpressed in cervical cancer tissues and necessary 
for the proliferation of cancer cells, while non-cancer cells are minimally affected. This 
suggests that KPNB1 mediated nuclear import is a possible target for anticancer therapeutics. 
This study investigates a novel small molecule inhibitor, as an experimental compound for 
nuclear import inhibition with anticancer properties. In addition, in vitro characterisation of 
the pharmacokinetics properties as well as the investigation of the in vivo toxicology of C53 
will be explored.  
 
1.9. Project Aims  
This project aims to: 
1) investigate the anticancer properties of a novel small molecule, C53 by monitoring its 
effects on cell proliferation, cell cycle and apoptosis using cervical cancer cell lines. 
2) investigate the effects of C53 on the activity of known KPNB1 target proteins. 
3) investigate the in vitro ADME pharmacokinetic properties of C53 to determine the 
solubility, lipophilicity, permeability, plasma protein binding and metabolic stability of 
C53. 









MATERIALS AND METHODS  
2.1 MATERIALS 
2.1.1 Cell lines 
Human cervical carcinoma cell lines, CaSki and HeLa, normal lung fibroblasts, WI38 as well as 
its transformed counterpart SVIWI38, were all obtained from American Type Culture 
Collection (ATCC, Rockville, MD, USA). The oesophageal carcinoma cell line WHCO6 was 
established originally from a South African patient with oesophageal squamous cell 
carcinoma, and was kindly provided by Prof R. Veale from the University of Witwatersrand, 
South Africa. KYSE30 was originally established by Shimada et al. and was purchased from the 
German Resource Centre for Biological Materials (Braunschweig, Germany) [64]. The normal 
skin fibroblasts FG0 and DMB were obtained from the Department of Medicine at the 
University of Cape Town.  
2.1.2 Chemical Compounds 
Compound 53, C53 (2S,4S)-1-benzyl-4-[(4-methoxy-1-naphthyl) methylamino]-N-methyl-
pyrrolidine-2-carboxamide was obtained from Syngene (ZINC identification no. 20598662) in 
a yellow/brown gum form at a 95% purity. C53 was dissolved in DMSO to a stock 
concentration of 100 mM and kept in the dark at room temperature. Inhibitor of nuclear 
import Importazole was purchased from Sigma-Aldrich (St Louis, MO, USA) and dissolved in 
DMSO to a stock concentration of 50 mM and stored at 4˚C. 
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2.1.3 Animals  
Animal ethics approval was obtained from the Faculty of Health Sciences Animal Ethics 
Committee, University of Cape Town (protocol number 016/ 014) for in vivo studies. Male and 
female athymic mice (UCT 21) of the age of 4-6 weeks were obtained from the Faculty of 
Health Science Animal breeding unit (University of Cape Town). Athymic mice were used 
because these mice are immunocompromised therefore they do not reject tumour cells from 
other species. The mice were housed 6 per cage in autoclaved polysufane cages with sterile 
wood shavings as bedding in a room kept at constant temperature and humidity in the BSL2 
unit (University of Cape Town). Mice were fed a regular autoclaved chow diet and water 
containing antibiotics and multi-vitamin. Mice were housed under 12-hour light and darkness 
cycles. Handling of mice was performed in strict accordance with the BSL2 guidelines of the 













2.2.1 Tissue cell culture 
All cells, except for the normal skin fibroblasts, were cultured in Dulbecco’s Modified Eagles 
Medium (DMEM) (Invitrogen, USA) containing 10% Fetal Bovine Serum (Gibico, Paisley, 
Scotland) and penicillin streptomycin (PS) (100 µg/mL). Normal skin fibroblasts were cultured 
in DMEM containing 20% Fetal Bovine Serum (FBS) supplemented with penicillin 
streptomycin (PS) (100 µg/mL). All cells were grown in 100 mm tissue culture dishes and 
incubated in a humidified incubator at 37˚C containing 95% air and 5% CO2. Media was 
changed every 2 days and cells were plated once ±70 % confluency was reached.  
2.2.1.3 Mycoplasma testing 
To ensure that cells were not contaminated with Mycoplasma, Mycoplasma tests were 
performed on all cell lines used. Cells were cultured as described in section 2.1.2, until they 
reached ± 70% confluency. Cells were then trypsinized then neutralized with media before 
centrifugation for 3 minutes. The pelleted cells were resuspended in PS-free media, plated on 
a cover slip and incubated for 24 hours. Cells were washed twice with 1 X PBS (pH 7.1) and 
fixed for 10 minutes. Cells were then stained with DAPI before being mount using mowiol and 
left overnight in the dark. The following day cells were visualized on the Zeiss Anxiovert 200 
inverted fluorescent microscope (Carl Zeiss, Jena, Germany). The presence of blue small 
speckles in the cytoplasm and cell membrane indicated mycoplasma contamination.  
2.2.2 MTT EC50 determination  
Cells were plated at 5000 cells/well in a 96-well plate and left to adhere overnight. Cells were 
treated with different concentrations of C53 for 48 hours. Following 48 hours of C53 
treatment, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent was 
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added (5 mg/ml) to the cells for 4 hours after which Solubilization reagent (10% SLS in  
0.01 M HCl) was added to each well to solubilize the crystals. Following 24 hours of incubation 
absorbance was read at 595nm.  Absorbance readings were used to plot a dose response 
curve and determine the EC50 (concentration of drug for half-maximal response) using the 
Graph pad prism software. 
2.2.3 Cell proliferation assay 
To measure the proliferation of cells, cells were plated at a density of 1000 cells/ well in a 96 
well plate. The following day cells were treated with varying concentrations of C53  
(0-40 µM) and viable cells were examined every 24 hours for 4 days using the MTT reduction 
assay method as previously described (section 2.3). 
2.2.4 Annexin V/PI Staining assay  
Apoptosis was examined by flowcytometry after staining with Propidium Iodide (PI)  
(100 µg/ml) and Alexa Fluor 488 annexin V (cell apoptotic marker). Briefly, cells were plated 
in 60 mm plates at a density of 1,5 x 105 cells/ plate and treated with either DMSO (control) 
or 20 and 40 µM C53 for 48 hours. Following treatment, cells were harvested, and staining 
method was carried out according to the manufacturer’s instructions (Alexa Fluor 488 
Annexin V/Dead Cell Apoptosis Kit, Introgen, OR, USA). After staining with Alex Fluor 488 
annexin v and PI binding buffer was added to the samples, mixed gently and analysed by flow 
cytometry. PI cannot penetrate live cells and apoptotic cells but penetrates dead cells, dying 
them with red fluorescence. The population of cells are distinguished based on the various 
fluorescence colours where live cells show little to no fluorescence, apoptotic cells show 
green fluorescence and dead cells show red and green fluorescence.  The percentage 
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population of apoptotic cells is determined by flow cytometry, measuring the fluorescence 
using 488 nm excitation and 530 nm emission. 
2.2.5 Western blot analysis 
2.2.5.1 Protein extraction and protein quantification  
2.2.5.1.1 Whole cell protein extraction 
Cells were grown to 70% confluency in a 60 mm cell culture dish and treated with appropriate 
concentration of C53 for a designated period. Media from each plate was collected in 12 mL 
tubes. Cells were washed twice with ice cold 1 X PBS and the PBS wash was added to the 
appropriate 12 mL tubes. A fixed volume (60 µl) of a cocktail (Active RIPA) containing 
radioimmunoprecipitation assay buffer (RIPA), 1 X complete protease inhibitor (Sigma, USA) 
and 1 mM Na3VO4 phosphatase inhibitor was added to each plate before cells were scraped 
using a cell scraper. Cell lysates were collected in eppendorf tubes and kept on ice. Cells 
collected in media (12 ml tubes) were centrifuged for 3 minutes at 10000 rpm. Pellets were 
resuspended in 40 µl Active RIPA and added to the cell lysates collected. Lysates were 
sonicated for 8 seconds then centrifuged at 4˚C for 10 minutes at 10000 rpm. The supernatant 
was transferred to new eppendorf tubes and protein was quantified using BCA (Bicinchoninic 
Acid) Assay (Pierce ThermoScientific, USA).  The BCA assay is based on the reduction of Cu+2 
to Cu+1 under alkaline conditions (Biuret reaction).  The reduction of Cu+2 by the protein is a 
function of protein concentration which was determined spectrophometrically by a colour 
change from green to purple measured at an absorbance of 595nm. Bovine serum albumin 
(BSA) standard curve was done using concentrations ranging from 50 µg/ml to 2000 µg/ml by 
adding 100 µl of the BCA working solution to 10 µl of each concentration in a 96-well plate. 
This was followed by a 30 minutes incubation at 37 ˚C, and absorbance values read at 595nm. 
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To determine protein concentration, 5 µl of protein extract was diluted with 15 µl of dH20 and 
the same procedure followed for BSA standard curve to obtain absorbance readings. Using 
the BSA standard curve protein concentrations were calculated.  
2.2.5.1.2 Nuclear Cytoplasmic fractionation  
To examine the change in localisation of a protein of interest (KPNB1) post treatment with 
C53, the nuclear proteins were harvested separately from the cytoplasmic proteins. Cells 
were plated and treated with varying concentrations of C53 for a designated period. After 
treatment, media from cells was removed and cells were washed twice with ice cold 1 X PBS 
followed by the addition of trypsin (600 µl) to dissociate cells. Complete media (600 µl) was 
added and cells were collected in eppendorfs on ice. Cells were centrifuged at 4˚C at 3000 
rpm for 5 minutes after which supernatant was discarded and pellet was resuspended in 
harvest buffer (150 µl) on ice for 5 minutes (recipes in appendix). After 5 minutes, cells were 
centrifuged at 5000 rpm for 10 minutes after which the supernatant (cytoplasmic fraction) 
was collected in new eppendorfs tubes and stored at -80˚C.  The nuclear pellet was 
resuspended in Buffer A (500 µl) and centrifuged at 5000 rpm for 5 minutes. The pellet was 
then slightly resuspended in Buffer C (150 µl) and vortexed for 15 minutes at 4˚C followed by 
centrifugation at 14000 rpm at 4˚C for 10 minutes. The supernatant which contained the 
nuclear proteins was collected in new eppendorf tubes and stored at -80˚C (recipes for buffers 
provided in appendix). Nuclear and cytoplasmic protein fractions were quantified using BCA 
as described in section 2.6.1.1. 
2.2.5.1.3 SDS-PAGE Gel Electrophoresis 
Fixed concentrations were loaded onto SDS-PAGE gel. 5X loading dye was added to the 
protein and total volume (30 µl) was made up using RIPA. Protein was denatured by heating 
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of the samples at 90˚C for 5 minutes using a heating block. Equal amounts of protein samples 
were loaded onto 10 -15% polyacrylamide gels and electrophoresis performed at 180 V for 
approximately 1 hour in 1X running buffer (recipe in appendix). After electrophoresis, the 
proteins were transferred onto a nitrocellulose membrane at 100 V for 70 minutes on ice 
using 1X transfer buffer (recipe in appendix). After transfer, the membrane was blocked in 5% 
Milk powder in TBST (TBS Tween) for 2 hours with gentle shaking.  
2.2.5.1.4 Antibody incubation 
After blocking, the membrane was washed three times with TBST for 5 minutes each. The 
membrane was probed with primary antibodies over night at 4˚C, gently shaking. (see Table 
2.6 for conditions). The following day the membrane was washed three times, 5 minutes each, 
with TBST to remove unbound antibody before probing with secondary antibody for 1 hour 
at room temperature with gentle shaking. Following incubation with secondary antibody, the 
membrane was washed a further three times with TBST for 5 minutes each. 
2.2.5.1.5 Immunodetection 
The protein bands of interest were detected using a chemiluminescent substrate system, 
LumiGlo (KPL, Gaithersburg, USA), according to manufacturer’s instructions. The membrane 
was incubated with equal volumes of each substrate for 1 minute. The protein bands were 
visualised by exposing the nitrocellulose membrane to X-ray films for a duration of time, 
followed by immersing film in developer (AGFA G128), water then fixative (AGFA G33C) 
followed by rinsing the membrane with water. The amount of GAPDH (whole cell and 
cytoplasmic protein) or Histone H3 (nuclear protein) was measure as an internal control. 
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2.2.5.1.6 Re-probing of membrane 
In order to investigate more than one protein on the same membrane re-probing was done. 
Membranes were stripped using 10% Acetic acid for 10 minutes gently shaking. Stripping is 
done to remove the primary and secondary antibodies of previous protein of interest to allow 
for re-probing of another protein. The membrane was washed with TBST to remove the acetic 
acid. The membrane was then blocked using 5% Milk in TBST for 2 hours while gently shaking 
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2.2.6 Cell cycle analysis  
The cell cycle profile of cells treated with C53 was determine by DNA staining with PI. Briefly, 
2 x 105 cells were plated in a 60 mm dish and treated with various concentrations of C53  
(0-40 µM) for 48 hours. Post treatment, the media was collected in 12 ml tubes on ice. The 
cells were washed twice with ice cold PBS before being trypsinized. Cells were collected in the 
same 12 ml tubes and pelleted at 10000 rpm for 2 minutes. The cells were then fixed with ice 
cold 100% ethanol and store at -20˚C for 3 days. Following fixation, cells were centrifuged and 
ethanol was removed. The cells were washed twice with ice cold PBS before the pellet was 
resuspended in ribonuclease (RNase)-PBS solution (50 µg/ml) and incubated for 30 minutes 
to remove the RNA. Following incubation cells were stained with staining solution containing 
PI (1 mg/ml) and incubated for a further 20 minutes. After staining, cells were analysed on a 
BD Accuri™ C6 flow cytometer (BD Biosciences, USA) and the cell cycle profile with the 
percentage of cells in each cell cycle phase was analysed using the ModFit LT™ software. 
2.2.7 Luciferase assays 
 The luciferase assays were used to monitor the activity of NFAT or NF-ĸβ regulated 
transcription. The rationale behind this assay is that the cargoes (NFAT or NF-ĸβ) need to be 
transported into the nucleus for transcription to take place, where transcription leads to 
fluorescence emission. Therefore, we used the luciferase assays to investigate whether C53 
treatment affects luciferase activity.  
To assay for NFAT luciferase activity, 30000 cells/well were plated in a 24-well plate and 
allowed to adhere overnight. The following day cells were transfected with 50 ng GFP-NFAT 
plasmid (Addgene plasmid #24219, [65]), 50 ng NFAT-Luciferase (Addgene plasmid #10959, 
[66]) and 5 ng Renilla with the addition of 0.4 µL of the transfection reagent Genecellin™ 
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(Celtric Molecular Diagnostic, South Africa). The following day transfection media was 
removed before treating cells with varying concentrations of C53 (0-40 µM) in fresh media 
for 24 hours. Cells were stimulated with 0.5 µM Phorbol Myristate Acetate (PMA) (Sigma) and 
1.3 µM Ionomycin (Santa Cruz Biotechnology, Ca, USA) 3 hours before the end of treatment. 
Ionomycin is added to increase Ca+2 flux which is required for NFAT activity while PMA is 
added to ensure full NFAT induction [67]. After treatment incubation, cells were washed twice 
with ice cold PBS then lysed using 1 X passive lysis buffer for 15 minutes. After lysis luciferase 
activity was assayed using the Dual-Luciferase® Reporter assay system (Promega) according 
to manufacturer’s instruction and activity was measured using the Veritas™ microplate 
luminometer (Promega). 
To assay for NF-ĸB/ p65 luciferase activity, 30000 cells/well were plated in a 24-well plate and 
allowed to adhere overnight. The following day cells were transfected with 50 ng NF-ĸB/p65 
luciferase reporter plasmid (Promega) and 5 ng Renilla using 0.4 µL GeneCellin™ transfection 
reagent. The following day cells were treated with varying concentrations of C53  
(0, 20 µM and 40 µM) for 24 hours and stimulated with 500 nM PMA for 3 hours before the 
end of the treatment incubation. Cells were then lysed using 1 X passive lysis buffer for  
15 minutes gently shaking after which luciferase activity was assayed using the Dual-
Luciferase® Reporter assay system (Promega) according to manufacturer’s instruction and 
activity measured using Veritas™ microplate luminometer (Promega). 
 
2.2.8 Immunofluorescence microscopy 
To analyse cellular localisation of KPNB1, cells were plated on ethanol flamed glass coverslips 
at 120 000 cells/ well in a 6-well plate. The following day cells were treated with the 
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appropriate treatment. Cells were then washed twice with ice cold PBS before being fixed 
using 4% paraformaldehyde in PBS for 15 minutes at room temperature. After fixing, fixing 
solution was removed and cells were washed twice with PBS. Cells were then permeabilized 
with 1 mL 0.25% Triton X-100 in PBS and incubated for 10 minutes at room temperature. 
Following permeabilization, cells were washed thrice with PBS before 1 ml blocking buffer 
(1% BSA in PBST + 0.3 M Glycine) was added to each well and incubated for 30 minutes.  After 
incubation cells were probed with primary antibody in blocking buffer for 1 hour followed by 
three 5 minutes washes with PBS. Then secondary antibody (Cy3 Goat anti Rabbit) in blocking 
buffer was then added to the cells and incubated at room temperature 1 hour in the dark. 
After the secondary antibody incubation, cells were washed with PBS then stained with DAPI 
(200 µg/mL) diluted in PBS (1:400) for 5 minutes. Cells were washed once with PBS before 
being mounted on the slide using mowiol. Slide was left to dry in the dark overnight. The 
following day images were visualised and captured using a Zeiss Anxiovert 200 inverted 
fluorescent microscope (Carl Zeiss, Jena, Germany).  The primary antibody used was rabbit 
anti-KPNB1 (Santa Cruz Biotechnology) diluted at 1: 100. Secondary antibody used was Cy3 
Goat anti Rabbit (Jackson ImmunoResearch, USA) diluted at 1: 300. 
2.2.9 ADME Pharmacokinetic assays 
In vitro ADME assays were performed with assistance from H3D Africa based at the University 
of Cape Town.  
2.2.9.1. Plasma protein binding assay  
The plasma protein binding assay was used to investigate the percentage of drug (C53) bound 
to plasma protein found in human blood plasma. The plasma protein binding of a drug has an 
impact on the drugs distribution in the body. 
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The plasma protein binding assay was performed in a 96-well micro titre plate with pooled 
human blood plasma (blood bank K3 EDTA). The blood plasma, which was thawed at 37˚C, 
was spiked with 10 mM stock of C53 (1 µM). The total concentration sample was prepared by 
immediately removing an aliquot of the human blood plasma spiked with C53 and quenching 
it with ice cold acetonitrile containing carbamazepine (0.0236 µg/ml, internal standard) then 
placed in the freezer. Duplicate aliquots of spiked plasma were transferred to a 96-well 
microtiter plate and incubated on a shaker at 37˚C for 30 minutes to allow for protein binding.  
After shaking, duplicate samples were then transferred to ultra-centrifuge tubes and 
ultracentrifuged (Beckman Optima L-80XP) at 37˚C for 4 hours. This allowed the separation of 
free drug from protein bound drug. Control samples Warfarin, MMV390048 and Caffeine 
were diluted in duplicates in blood plasma protein in a 96-well plate and incubated on the 
shaker for 4 hours at 37˚C. After 4 hours, aliquots (40 µl) of both samples and controls were 
transferred to a 96-well deep well plate and quenched with ice cold acetonitrile with 
carbamazepine (0.1 µM, internal standard). All samples were then centrifuged at 3000 rpm 
for 10 minutes and resulting supernatant was filtered. Analyte concentration of compound 
samples (containing C53) as well as controls were determined by LC-MS/MS (Agilent Rapid 
Resolution HPLC, AB SCIEX 4000 QTRAP MS). 
2.2.9.2 Kinetic solubility 
The Kinetic solubility assay was performed to investigate the solubility of C53 in an aqueous 
medium. The kinetic solubility assay was performed using a miniaturised shake flask 
method. Briefly, C53 was dissolved in DMSO to a stock concentration of 10 mM. The 10 mM 
stock solution was used to prepare calibration standards (10-220 µM) in DMSO and added 
to phosphate buffer (PBS, pH 7.4) to a final DMSO concentration of 2%. Solutions were 
shaken for 2 hours at  
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25˚C to allow solubilisation of test compound (C53). Solutions were filtered and analysed by 
HPLC-DAD (Agilent 1200 Rapid Resolution HPLC with diode array detector). The aqueous 
solubility of samples was determined using a best fit calibration curve constructed from the 
calibration standards [68]. 
2.2.9.3 Parallel Artificial Permeability Assay (PAMPA) 
PAMPA is an in vitro assay used to investigate the passive transcellular permeability of a 
drug. For a drug to enter the circulatory system it needs to pass through membranes, hence 
PAMPA assay mimics these membranes to monitor permeability of a compound. 
The PAMPA assay was performed in 96-well MultiScreen Filter plates (Millipore, 0.4 µM PCTE 
Membrane), in triplicates. The membrane filters were pre-coated with 5% hexadecane in 
hexane and allowed to dry before the start of the assay. The wells of the 96-well donor plate 
were filled with buffer (pH 6.5), spiked with C53 (1 µg/mL). Membrane integrity marker, 
Lucifer yellow, was added to the wells of the MultiScreen donor plate. Phosphate buffer  
(pH 7.4) was added to the 96-well acceptor plate. The donor plate was then slotted into the 
acceptor plate forming a sandwich assembly then incubated for 4 hours at room temperature, 
gently shaking (50 rpm) to allow passive diffusion of compound. Following incubation, 
samples from acceptor wells were transferred to the analysis plate and acetonitrile containing 
carbamazepine (0.0236 µg/mL) was added to the samples before analysis by LC-MS/MS 
(Agilent Rapid Resolution HPLC, AB SCIEX 4500 MS). Membrane integrity was analysed by 
calculating the apparent permeability (Papp)of Lucifer yellow using Modulus microplate reader 
[69]. The normalised peak areas were used to calculate the Papp for the samples. 




The lipophilicity assay was used to investigate the lipophilicity of C53 which refers to how well 
a compound dissolves in fats/oils. The lipophilicity of a drug is important as it affects the 
solubility and metabolism of a drug. 
The lipophilicity assay makes use of the shake flask method. Experiments were done in 
triplicate. Briefly, 10 µL of C53 (10 mM) was added to a 1:1 mixture of phosphate buffer  
(pH 7.4) and n-octanol in a microtiter plate. The solutions were shaken (1500 rpm) for 2 hours 
at room temperature.  Following shaking, samples were centrifuged to fully separate the 
octanol/ PBS layers. The samples were analysed by HPLC-DAD (Agilent 1200 Rapid Resolution 
HPLC with diode array detector) to determine the partition coefficient (LogD7.4) [70]. This was 
done by determining the amount of compound in each layer (PBS and n-octanol).   
2.2.9.5 Microsomal Stability 
The metabolic assay was performed to investigate how quickly C53 is broken down by 
metabolic enzymes to determine the half-life and clearance of the compound.  
The metabolic assay was performed in a 96-well microtiter plate, in duplicates. 1 µM of C53 
was incubated individually in mice, rat and pooled human liver microsomes (0.4 mg/mL) at 
37˚C at varying time points. Incubation was done in the absence and presence of the cofactor 
NADPH (1 mM). Reactions were quenched at the various time points by adding 300 µL 
acetonitrile containing the internal standard, carbamazepine (0.0236 µg/mL). The amount of 
C53 in the supernatant was then analysed by LC-MS/MS (Agilent Rapid Resolution HPLC, AB 
SCIEX 4000 QTRAP MS) to determine the disappearance of the parent compound which is 
used to determine the half-life and clearance of the compound. Metabolite searches were 
not conducted within this assay [71]. 
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2.2.10 C53 Toxicology studies in vivo  
In order to investigate whether C53 is tolerable in nude mice a toxicology pilot study was 
performed. A total of 24 nude mice were randomized into four groups of six mice each. The 
three test groups received 10 µg/g, 30 µg/g and 50 µg/g of C53 in 7.5% DMSO in PBS while 
the control group received 7.5% DMSO in PBS only. Mice were injected interperitoneally (i.p) 
twice per week for 28 days. The mice were weighed four times a week and their well-being 
was monitored daily for the entire experimental period. At the end of 28 days, mice were 
euthanized by halothane over dose. Autopsies of each mouse was performed by an animal 
technician from the animal unit at UCT to analyse if drug caused any toxic effects internally. 
Signs of toxicity include inflammation of organs mainly the liver, discolouration of organs or 
unusual deposits at sight of injection. The liver of each mouse was then removed and 
weighed.  
2.2.11 Statistical analysis 
All experiments were performed at least two independent times. Experiments were 
performed in duplicates, triplicates or quadruplicates and expressed as mean ± standard error 
of mean (SEM), unless stated otherwise. The statistical significance was determined using the 
two-tailed student t-test (paired) using Microsoft Excel where a p-value of < 0.05 was 













Targeted therapies are a form of cancer treatment that target key characteristics in malignant 
cells responsible for driving tumorigenesis. The advantage of this form of therapy is its 
specificity for targeting pathways on which cancer cells are dependent on [72]. The 
identification of the altered expression of KPNB1 in cervical cancer patient tissue and cell lines 
in comparison to normal cell lines as well as the induction of apoptosis in cancer cells lines 
after inhibition of KPNB1 expression suggests a dependency of cervical cancer cell lines on 
KPNB1 function [17,44]. These studies suggest that KPNB1 has potential as an anticancer 
therapeutic target. 
There are multiple ways in which a protein target can be inhibited. One manner is the use of 
a small molecule inhibitor that targets the protein of interest. An investigation of possible 
inhibitors of KPNB1 through structure based in silico screening and cell based assays 
performed by our laboratory in collaboration with researchers at the University of Louisville 
identified a number of potential small molecule inhibitors of KPNB1, including compounds 
named C43 (INI43) and Compound 53 (C53). Extensive research has been done on INI43, 
which revealed that it has anticancer properties as well as nuclear import inhibition properties 
[62]. The aim of this study is to investigate the anticancer properties of the previously 
undescribed compound, C53 on cancer cell biology. Different aspects of cancer cell biology 
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were investigated including cell survival, proliferation, cell cycle progression and cell death 
inducing mechanism. 
To investigate the potency of a drug-like compound the half maximal effective concentration 
(EC50) is measured. The EC50 is defined as the concentration of a drug required to induce a  
50% response after a specified exposure time [73]. Therefore, to investigate the cell survival 
of cancer cells we determined the EC50 of C53 in a panel of cell lines. For the assessment of 
the effect of C53 on proliferation, cancer cells were treated with C53 and proliferation was 
monitored over a specified period. Since cancer cells are characterised by uncontrolled 
proliferation an anticancer agent should ideally reduce the proliferation of cancer cells. 
Research has shown that the aberrant cell proliferation that characterises cancer associates 
with alterations in cell cycle progression [74]. To investigate the effect of C53 on cell cycle 
progression we monitored the cell cycle profile of cells treated with C53 by flow cytometry.  
In order to investigate whether C53 induces cell death, we analysed the morphology of cells 
post treatment with C53. Cells undergoing cell death are characterised by specific 
morphological features e.g apoptotic cells have blebbed membranes; autophagic cells are 
characterised by vacuoles (autophagosomes) while necrotic cells are usually burst open. The 
mode of cell death was further investigated by Annexin V/PI staining which distinguishes the 
percentage of cells undergoing cell death and determines whether the cell death is apoptotic. 
In viable cells, phosphatidylserine (PS) is located on the inner membrane of the cell 
membrane. However, in apoptotic cells PS is translocated to the outer leaflet of the 
membrane. Annexin V/PI staining is useful in detecting apoptotic cells because the Annexin V 
binds to the translocated PS on apoptotic cells.     
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3.2 RESULTS  
3.2.1 EC50 determination for C53 in non-cancer cells, cervical and oesophageal cancer cell 
lines.  
The EC50 (concentration of drug required to produce a half maximal response) of C53 was 
determined in a panel of cancer (CaSki, HeLa, Kyse30, WHCO6, transformed (SVIWI38)) and 
non-cancer (FG0, WI38, DMB) cells. Cells were plated in a 96-well plate and treated with 
varying concentrations of C53 for 48 hours after which MTT reagent was added to quantify 
the number of viable cells. Absorbance readings of viable cells were analysed using Hill plots 
and EC50 values determined (Figure 3.1). The EC50 results with 95% confidence intervals are 
tabulated in Table 3.1 and show that CaSki and HeLa cervical cancer cells as well as Kyse30 
and WHCO6 oesophageal cancer cells had EC50 values of approximately 20 µM. The 
transformed fibroblast cell line SVIWI38, had an EC50 value of 27 µM while the non-cancer 
fibroblasts had EC50 values of between 30 and 40 µM. These results show that C53 has a cell 
killing effect of ~20 µM in cancer cells which is 1.5-2 fold lower than that of non-cancer 









Figure 3.1 EC50 determination in cervical cancer, oesophageal cancer and non-cancer cells. 
Cervical cancer (HeLa and CaSki) cells, Oesophageal cancer (Kyse30 and WHCO6), 
transformed fibroblast cell line, SVIWI38 and non-cancer fibroblast (WI38, FG0 and DMB) cells 
were treated with increasing concentration of C53 for 48 hours after which viable cells were 
examined by an MTT assay. Hill plots and EC50  values were quantified using Graph Pad Prism 
software. Experiments were performed in triplicate and repeated at least two independent 
times. Representative hill plots are shown.  
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Table 3.1: Average EC50 values of C53 in cervical and oesophageal cancer cell lines as well as 
non-cancer cells  
 
 
Figure 3.2. A summarised graph of the average C53 EC50 values in cervical, oesophageal and 
non-cancer cells. MTT assay was used to determine EC50 values in cancer and non-cancer cell 
lines. The non-cancer (black) cells show higher EC50 values than the cancer cell lines  
(clear bars). Experiments were performed in triplicate and repeated at least two independent 
times. 
 Cell line EC50 value (µM) 95 % Confidence 
Interval 
Cervical cancer CaSki 20.8 19.3 – 22.3 
Cervical cancer HeLa 20.2 16.4 – 25.1 
Oesophageal cancer Kyse30 20.1 16.4 – 24.6 
Oesophageal cancer WHCO6 20.5 16.2 –  26.2 
Transformed  SVWI38 27.1 20.8 – 35.6 
Fibroblast WI38 31.8 24.2 - 41.8 
Fibroblast FG0 30.6 28.2 – 38.7 
Fibroblast DMB 39.9 35.0 – 45.5 
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3.2.2 Effect of C53 on cell proliferation of cervical cancer cells and normal fibroblast. 
Having established that C53 has enhanced cytotoxic effects on cervical and oesophageal 
cancer cell lines which have shown elevated expression of KPNB1 in comparison to normal 
fibroblasts, we next investigated the effect of C53 on cell proliferation of cervical cancer cell 
lines which was the focus of this MSc thesis. For this assay, cervical cancer cell lines HeLa and 
CaSki as well as normal fibroblast FG0 were treated with the vehicle control, DMSO or 10 µM, 
20 µM (EC50) and 40 µM C53 and cell proliferation was evaluated over four days using the 
MTT assay. Cell proliferation was quantified and the results show that 20 µM and 40 µM C53 
treatment significantly reduced the cell proliferation of HeLa and CaSki cell lines while 10 µM 
C53 only showed inhibitory effects at day 4 of C53 treatment (Figure 3.3 A and B).  C53 
treatment at 10 µM and 20 µM concentrations had little effect on the proliferation of non-
cancer FG0 cells however, 40 µM C53 treatment inhibited the proliferation of FG0 (Figure 3.3 
C). These results show that C53 selectively reduces the proliferation of cancer cell lines at 





















Figure 3.3 Effect of C53 on the cell proliferation of HeLa, CaSki and FG0 cells. Cells were 
plated and treated with increasing concentrations of C53 or DMSO (control) and cell 
proliferation was measured by MTT assay over 4 days. (A) HeLa and (B) CaSki cells showed a 
reduction in cell proliferation for 20 µM and 40 µM while proliferation reduction was seen at 
day 4 for 10 µM C53. (C) FG0 proliferation was unaffected for 10 µM and 20 µM C53 treatment 
however 40 µM C53 has an effect. Experiments were performed in triplicate and repeated 
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3.2.3 Effect of C53 on cell cycle progression of cervical cancer cells lines. 
Since C53 had inhibitory effects on the cell proliferation of both HeLa and CaSki cell lines, cell 
cycle analysis was performed to determine if the inhibitory effects were associated with 
alterations in cell cycle progression. Cell cycle analysis was performed on both HeLa and CaSki 
cell lines treated with either DMSO (control) or 20 µM and 40 µM C53 for various time points. 
For CaSki cells treated with C53, an increase in the G1 phase with a decrease in the S and 
G2/M phase was observed (Figure 3.4 A). Quantification of the data shows a significant 
increase in the percentage of cells in the G1 phase and a significant decrease in the 
percentage of cells in the S and G2/M phase of the cell cycle (Figure 3.4 B). A significant 
increase in cells in the SubG1 phase was observed at 40 µM C53. For HeLa cells, cell cycle 
analysis similarly showed an increase in G1 phase with a decrease in the S phase for both the 
20 and 40 µM C53 treatment (Figure 3.5 A). Quantification of the results showed a slight but 
significant increase in G1 phase with a decrease in S phase (Figure 3.5 B). Together, these 
results suggest that C53 treatment results in a delayed G1/S progression. These effects 










Figure 3.4 C53 induces a G1-phase cell cycle arrest in CaSki cell line.  Cells were plated and 
treated with either DMSO (control) or 20 and 40 µM C53 for 48 hours after which cell cycle 
analysis was done using a flow cytometer. (A) CaSki cell cycle profiles show a decrease in S 
and G2/M phase for 20 and 40 µM C53 treatment. Cell cycle profiles also show an increase in 
the SubG1 phase for 40 µM C53 treatment (B) Quantified cell cycle analysis 48 hours post 
treatment with C53 show a significant increase in G1 with a decrease in S and G2/M phase for 
20 and 40 µM C53. Result values indicate the mean ± SEM of experiments performed in 
triplicate and repeated at least two independent times (*p< 0.05). 
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Figure 3.5 C53 induces a G1-phase cell cycle arrest in HeLa cell line.  Cell cycle profile of HeLa 
cells treated with either DMSO or 20 and 40 µM C53 for 48 hours after which cells were 
analysed using a flow cytometer. (A) Cell cycle profiles shows a slight increase of G1 phase for 
20 and 40 µM C53 with a decrease in S phase for 20 µM and 40 µM C53 treatment. Profile 
also shows an increase in Sub G1 for 40 µM C53 treatment (B) Quantified cell cycle analysis 
of HeLa cells 48 hours post treatment with C53. Results show a slight significant increase in 
G1 with a decrease in S phase for both 20 µM and 40 µM C53 treatment. Results indicate the 
mean ± SEM of experiments performed in triplicate and repeated at least two independent 
times (*p< 0.05). 
B 
A 
DMSO 20 µM C53 40 µM C53 
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3.2.4 The effect of C53 on markers associated with cell cycle progression 
In the cell cycle of vertebrate cells, preparation for the S phase takes place in the G1 phase 
which is triggered by regulation of cyclin D1-CDK4/6 complex. The formation of this complex 
regulates DNA synthesis and promotes the progression of cells through G1-S phase of the cell 
cycle [75]. To explore the potential mechanism by which C53 causes a delayed G1/S 
progression, protein expression levels of cell cycle markers were investigated in HeLa and 
CaSki cell lines in response to 20 µM and 40 µM C53 treatment for 48 and 72 hours. The 
markers examined included proteins expressed in G1 phase; cyclin D1 and CDK4. Western blot 
analysis for Cyclin D1 and CDK4 showed that treatment with 20 and 40 µM C53 resulted in a 
reduction in Cyclin D1 and CDK4 levels at 48 and 72 hours in both HeLa and CaSki cell lines  
(Figure 3.6 A and B). These results support the cell cycle analysis data showing that C53 



















Figure 3.6 Effect of C53 on G1 phase cell cycle markers. (A) HeLa and (B) CaSki cells were 
plated and treated with either DMSO or 20 µM and 40 µM C53 for 48 or 72 hours. Cell cycle 
markers were investigated via western blot, with GAPDH as the loading control. Results show 
a decrease in the amount of CyclinD1 and CDK4 for both HeLa and CaSki cell lines. Results 
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3.2.5 C53 induces cell death via apoptosis. 
3.2.5.1 Monitoring morphological changes induced by C53 treatment.  
Having established that C53 inhibited cell proliferation and blocked cell cycle progression we 
next investigated the mechanism of cell death associated with C53. Different forms of cell 
death can be characterised by morphological criteria and classified as either apoptotic, 
necrotic or autophagic. Apoptotic cells are morphologically characterised by cell shrinkage, 
membrane blebbing and condensation of the chromatin while necrosis is characterised 
cytoplasmic and organelle swelling followed by bursting of the cell releasing cell content into 
extracellular space. In the case of autophagy (which can be catabolic or pro-survival), 
autophagic cells can be characterised by the formation of autophagic vacuoles known as 
autophagasomes [76].  
To understand the mode of cell death induced by C53, HeLa and CaSki cells were treated with 
20 µM or 40 µM C53 for 48 hours and the morphology of the cells were observed using phase 
contrast microscopy. Images captured using light microscopy show healthy cells for the 
control HeLa and CaSki cell lines (Figure 3.7 A). The presence of rounded cells showing signs 
of membrane blebbing was observed at 20 µM C53 treatment (Figure 3.7 B). Both HeLa and 
CaSki cell lines treated with 40 µM C53 showed substantially more cell shrinkage  
(Figure 3.7 C). These morphological changes suggest that C53 may be inducing cell death 
through apoptosis. 







Figure 3.7. The morphological effect of C53 treatment. HeLa and CaSki cells were treated 
with either (A) DMSO or (B) 20 and (C) 40 µM C53 for 48 hours. Images show an increase in 
shrank rounded cells for 20 and 40 µM C53 for both HeLa and CaSki cell lines. Images were 
captured with a Primovert inverted light microscopy at 20X magnification. Yellow arrows 
indicative of rounded and lifting cells. Blue arrows show signs of membrane blebbing 
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3.2.5.2 Annexin V/PI staining shows C53 treatment causes cell death by apoptosis. 
Results from morphological analysis of HeLa and CaSki cells post C53 treatment suggested 
that the cells were undergoing apoptosis. To confirm this, Annexin V/PI assays were 
performed using HeLa and CaSki cells that were treated with either DMSO (control) or 20 µM 
and 40 µM for 48 and 72 hours. The Annexin V/PI staining assays distinguished cells as live, 
early apoptotic, late apoptotic and dead. This assay can distinguish early apoptotic cells from 
late apoptotic cells because late apoptotic cells are Annexin V positive and PI positive because 
the membrane of late apoptotic cells are disintegrated therefore allowing PI staining to enter 
the cells and bind the DNA while the membrane of early apoptotic cells are still intact 
therefore not allowing PI staining but allowing for binding of Annexin V on PS. Therefore, late 
apoptotic cells and early apoptotic cells can be distinguished in the Annexin V/PI staining 
assay. The results showed a small but significant decrease in live cells and an increase in early 
and late apoptotic cells for both HeLa and CaSki cell lines treated with C53 for 48 hours (Figure 
3.8 A). At 72 hours treatment, a substantial and significant decrease in the percentage of live 
cells for both HeLa and CaSki cell lines was observed and an associated increase in early and 
late apoptotic cells was observed in both 20 µM and 40 µM C53 treatment (Figure 3.8 B). 
These results confirm that C53 treatment triggers apoptosis of cervical cancer cell lines. The 































Figure 3.8. C53 induces apoptosis. CaSki and  HeLa cells were plated and treated with either 
DMSO (control) or 20 µM and 40 µM C53 for 48 hours or 72 hours after which cells were 
stained using the Alexa Fluor 488 Annexin V/Dead Cell Apoptosis Kit and analysed by flow 
cytometry. (A) Results show a small but significant decrease in percentage of live cells at 48 
hours C53 treatment with an increase in apoptotic cells. (B) At 72 hours there is a substantial 
decrease in the percentage of live cells and an increase in the percentage of apoptotic cells in 
both HeLa and CaSki cell lines. Results shown are the mean ±SEM of experiments performed 
in triplicate and repeated at least two independent times (*p< 0.05). 
A 
B 
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3.2.5.3 C53 induces PARP cleavage 
Results from the morphological images and Annexin V/PI assay showed that C53 induces 
apoptosis in a time dependent manner. To further validate these results, the protein level of 
Poly (ADP-ribose) Polymerase (PARP) was investigated in HeLa and CaSki cell lines in response 
to C53. PARP is a known substrate of Caspase 3 and is cleaved from 116 KDa to an 89 KDa 
fragment during early apoptosis [77]. The presence of cleaved PARP was evaluated by western 
blot analysis after C53 treatment at 48 and 72 hours for HeLa and CaSki cells. The results 
showed a dose dependent increase in cleaved PARP at 48 and 72 hours treatment for HeLa 
cells (Figure 3.9 A). CaSki cells similarly showed the presence of cleaved PARP after C53 
treatment (Figure 3.9 B). The presence of cleaved PARP is an independent confirmation that 








































Figure 3.9 C53 Induces PARP cleavage.  HeLa and CaSki cells were both treated with DMSO 
or 20 µM and 40 µM C53 for 48 or 72 hours. PARP cleavage was investigated via western blot, 
with GAPDH as a loading control. (A) HeLa and (B) CaSki cells showed an increase in cleaved 
PARP in a time and concentration dependent manner. Results shown are representative of 
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3.3 DISCUSSION  
This chapter focused on testing the anticancer properties of a novel pyrrolidine derivative, 
C53. We report that C53 inhibits the proliferation of cervical cancer cells and induces a delay 
in G1/S cell cycle progression as well as cell death via apoptosis. 
C53 (1-benzyl-4[(4-methoxy-1-naphyl) methylamino]-N-methyl-pyrrolidine-2-carboxamide) a 
potential small molecule inhibitor of KPNB1 is a pyrrolidine derivative. There are reports in 
literature that show pyrrolidine derivatives having anticancer activity. A study done by Wana 
et al. showed the development and synthesis of a series of pyrrolidine derivatives that 
showed anticancer activity through the inhibition of Mcl-1 in MDA-MB-231 (breast cancer), 
PC-3 (prostate cancer) and K562 (chronic myelogenous Leukemia cell) cell lines [78]. Another 
study done on pyrrolidine derivatives showed that a caffeoyl pyrrolidine derivative inhibits 
tumour invasion and metastasis through the suppression of matrix metalloproteinase activity 
[79]. The use of pyrrolidine derivatives for targeted cancer therapies shows their potential as 
anticancer compounds.  
Previous work in our lab extensively investigated a small molecule inhibitor of KPNB1, INI43. 
Like C53, INI43 was selected from an in silico study investigating several compounds with 
potential to bind KPNB1 and inhibit its nuclear import function. INI43 showed anticancer 
activity in cervical cancer cells lines as well as inhibitory effects on KPNB1 mediated  
transport [64]. To date small molecule inhibitors which target nuclear import are limited. 
Most research has focused on Selective Inhibitors of Nuclear Export (SINEs). The first 
identified SINE was Leptomycin B, which was an inhibitor of the nuclear export protein CRM1. 
However, due to toxic side effects in clinical trials, Leptomycin B was discontinued [80]. The 
discovery of Leptomycin B led to the development of other SINE which include Atjadone C, 
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Anguinomycin, Aoniothalamin, as well as the small molecule inhibitors, N-azolylacrylates and 
CBS9106 [81]. These compounds were shown to bind CRM1 and stop cell proliferation in 
cancer cells. In recent years, more small molecules SINE of CRM1 have been developed e.g 
KPT-185 and Selinexor. KPT-185 was investigated extensively in vitro and showed promise 
however, in vivo study of the compound was unsuccessful due to poor pharmacokinetics [82]. 
This led to the development of Selinexor, the first small molecule SINE to reach clinical trials. 
SINEs are now being explored in many clinical trials as anticancer agents. This evidence 
highlights the potential in the inhibition of nuclear transport in cancer cells.  
With Importazole being one of the few commercially available inhibitors of nuclear import 
further extensive research and development, like that of SINEs, is required for nuclear import 
inhibition [60]. Like CRM1, KPNB1 was also shown to be overexpressed in various 
malignancies thus shows potential as an anticancer target. The results in this chapter provides 
preliminary evidence of the anticancer effects of the novel small molecule inhibitor of nuclear 





   








KPNB1 has been shown to play a key role in importing cargoes into the nucleus through two 
major pathways known as the non-classical and classical pathways [32,34]. Cargoes imported 
by KPNB1 in the classical import pathway include Stat3, NF-ĸB and NFAT which are only 
activated once in the nucleus [44]. Examples of cargoes imported in the non-classical import 
pathway include Snail [83] and Parathyroid Hormone‐related Protein (PTHrP) [78]. There are 
some cargoes imported by KPNB1 which have been implicated in cancer such as Snail, NF-ĸB, 
Stat3 and NFAT [85]. Inhibition of KPNB1 therefore has an advantage of inhibiting the import 
of cargoes which have been associated with tumorigenesis.  
KPNB1 has been shown to be overexpressed in cancer cells and appears to be more reliant on 
KPNB1 function than non-cancer cells [17,44]. This led to the proposal that KPNB1 has 
potential as a druggable target [17]. The first small molecule inhibitor of KPNB1 identified is 
Karyostatin A1. Karyostatin A1 was shown to bind KPNB1 with high affinity and specifically 
targeted the classical import pathway in vivo and in vitro [59]. A commercially available KPNB1 
inhibitor, Importazole has been shown, through FRET-based studies, to interfere with the 
interaction of KPNB1 and RanGTP therefore blocking KPNB1 mediated nuclear import 
however, no anticancer properties were investigated in this study [60]. Therefore, there is a 
search for novel KPNB1 inhibitors with anticancer properties.  
72 
Using a structure based in silico approach our study identified C53 as a potential small 
molecule inhibitor of KPNB1. In the previous chapter, we reported that C53 has anticancer 
properties using cervical and oesophageal cancer cell lines. In this chapter, we investigated 
the effect of C53 treatment on the nuclear activity of KPNB1 cargo proteins; NFAT and NF-ĸB 
transcription factors. The activity of these transcription factors was monitored using the NFAT 
or NF-ĸB/p65 dual reporter assays as a measure of nuclear presence and activity. The effect 
of C53 on the localisation of KPNB1 was also investigated using immunofluorescence and 
nuclear cytoplasmic fractionation. 




4.2.1 Investigating the effect of C53 on KPNB1 mediated cargo import 
For cargoes to be imported by KPNB1 through the non-classical or classical import pathway 
they must be recognized through specific NLSs. Previous studies have shown a number of the 
cargoes imported by KPNB1 e.g. NF-ĸB and nuclear factor of activated T cells (NFAT) are 
implicated in cancer [85,86]. Therefore, the inhibition of the nuclear import of these cargoes 
may have implications for cancer cells.  
In this section, we investigated the effect of C53 treatment on the activity of NFAT and  
NF-ĸB/p65 using the dual reporter luciferase activity assay. Transcriptional activity was used 
as a measure of functional activity of NFAT and NF-ĸB in the nucleus. 
4.2.1.1 C53 treatment inhibits NFAT nuclear activity 
For the NFAT pathway to be activated there needs to be a calcium flux which drives the 
dephosphorylation of NFAT by the protease, Calcineurin (Cn). This dephosphorylation 
exposes the NLS found on NFAT which is recognized by KPNα. After recognition, a trimeric 
complex (KPNα, NFAT and KPNB1) is formed which translocate from the cytoplasm into the 
nucleus. In the nucleus, NFAT dissociates from the Karyopherins and initiates the transcription 
of downstream targets such as Interleukin-2 (IL-2), Interleukin-10 (IL-10) and Interferon 
gamma (IFNγ) [87].  
As previously mentioned there are several karyopherin B-like receptors which import 
different protein into the nucleus through specific NLS recognition [37]. In the case of the 
NFAT transcription factor, research has shown that it is shuttled between the nucleus and 
cytoplasm in a KPNB1- dependent manner through the classical import pathway [88]. Since 
NFAT contains an NLS which is recognized by KPNα/KPNB1, we anticipated that C53 would 
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influence the transcriptional activity of NFAT on the basis that C53 was selected as a potential 
small molecule inhibitor of KPNB1 and NFAT is dependent on KPNB1 for nuclear import. The 
presence and transcriptional activity of NFAT was measured through a NFAT reporter 
luciferase assay (Figure 4.1).  
For this assay, HeLa cells were transfected with GFP-NFAT and NFAT Reporter (Luc) plasmids. 
Control and C53 treated cells were stimulated with PMA and Ionomycin for 3 hours and cell 
lysates were harvested for luciferase assays. As described by Northrop et al.  PMA is added to 
activate NFAT import while Ionomycin is added to induce the calcium flux [89]. Our results 
show a significant increase in NFAT activity in cells co-stimulated with PMA and Ionomycin 
indicative of NFAT nuclear import and activation. C53 treatment at 20 µM and 40 µM resulted 
in a slight but significant decrease in NFAT activity (Figure 4.1 B). Since only live cells were 
harvested reduction in transcriptional activity is not due to apoptosis.  Decrease in NFAT 
transcriptional activity is ~ 1.3 fold. The physiological relevance of this is not yet clear at 
present. There are examples in literature that have shown slight but significant decreases in 
NFAT transcriptional activity such as Importazole which showed a ~1.4-1.6 fold decrease as 
well as Ivermectin which showed a ~1.4 fold decrease in NFAT transcriptional activity [62]. 




















Figure 4.1. Treatment with C53 results in a downregulation of NFAT transcription activity. 
(A) Diagrammatic representation of the NFAT assay. (B) HeLa cells were transfected with GFP-
NFAT plasmid (50 ng) and treated with DMSO (control) or 20 µM and 40 µM C53 for 24 hours. 
Three hours before the termination of treatment cells were stimulated with 0.5 µM PMA and 
1.3 µM Ionomycin. Cells were harvested for analysis by luciferase assay.  Promoter activity 
was normalized to Renilla. Results show a significant decrease of NFAT activity after C53 
treatment. Experiments were performed in quadruplicate and repeated at least two 
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4.2.1.2 C53 treatment reduces NF-ĸB/p65 transcriptional activity 
NF-ĸB is a transcription factor which plays a role in inflammation, proliferation and apoptosis. 
A well-defined subunit of NF-ĸB is the p50/p65 dimer. This dimer, in its inactive form, is bound 
to IĸB which is usually localized in the cytoplasm. Upon stimulation by cytokines or stressors, 
the classical NF-ĸB pathway is activated. A IKK complex which compromises of catalytic units 
phosphorylates IĸB which triggers its degradation. This then frees the NF-ĸB (p50/p65) 
subunit exposing its NLS to be recognized by the nuclear transport proteins for import into 
the nucleus where it activates gene expression [90]. The NF-ĸB transcription factor contains 
classical NLS motifs which when recognized initiates nuclear import via the KPNB1-dependent 
classical nuclear import pathway. Studies have shown that TNFα-activated NF-ĸB 
heterodimers are transported into the nucleus after recognition by importin α3 or importin 
α4 both of which interact with KPNB1 [91]. We therefore investigated the effects of C53 on 
NF-ĸB activity as it is a known KPNB1 cargo.  
For this assay, HeLa cells were transfected with promoter reporter plasmid containing an  
NF-ĸB consensus binding site included in a minimal promoter. Renilla-Luciferase was used as 
a control for transcription efficiency. The cells were treated with either DMSO (vehicle) or  
20 µM and 40 µM C53 for 24 hours followed by stimulation with PMA 3 hours prior to 
termination of C53 treatment. Cell lysates were harvested, and luciferase activity monitored 
as a measure of NF-ĸB activity. Results showed a significant decrease of NF-ĸB/p65 dependent 
transcription activity with 20 µM and 40 µM C53 treatment compared to that of the PMA 
stimulated control cells (Figure 4.2). These results suggest that C53 treatment significantly 
inhibits NF-ĸB/p65 dependent transcription activity in a dose dependent manner.  
 


























Figure 4.2. C53 treatment reduces the luciferase transcriptional activity of NF-ĸB p65.  
NF-ĸB/p65 luciferase reporter assay revealed a significant decrease in p65 activity for cells 
treated with 20 µM or 40 µM C53 for 24 hours. Results were normalized to Renilla-Luciferase 
as a control for transcription efficiency. Experiments were performed in quadruplicate and 
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4.2.3. Comparison of the effects of C53 to that of commercially available KPNB1 inhibitor, 
Importazole on NFAT activity. 
Having shown that C53 significantly reduces NFAT and NF-ĸB import activity we were 
interested in comparing its effects with that of commercially available KPNB1 inhibitor, 
Importazole. Importazole has been shown to interfere with KPNB1 mediated import [60]. 
Experiments were set up as described previously. Results showed an increase in NFAT activity 
in HeLa cells with PMA and Ionomycin which correlates with NFAT nuclear import. Treatment 
with 20 µM and 40 µM C53 resulted in a significant decrease in NFAT activity, as previously 
observed (Figure 4.3 A). The results of C53 or Importazole treatment similarly inhibited NFAT 
activity at both 20 µM and 40 µM (Figure 4.3 B). These results show that C53 has similar 



























Figure 4.3. Comparison of the effects of C53 or Importazole on NFAT activity. Results of the 
NFAT luciferase activity assay revealed that (A) C53 inhibits NFAT activity in a similar manner 
to that of (B) Importazole after 24 hours of treatment. Promoter activity was normalised to 
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4.2.4. The effect of C53 on KPNB1 localisation 
Having established that C53 inhibits the nuclear import and activity of NFAT and NF-ĸB we 
next investigated the effect of C53 on KPNB1 localisation. The localisation of KPNB1 was 
investigated by immunofluorescence assays. 
Briefly, HeLa cells were plated on cover slips and treated with either DMSO (vehicle) or 20 µM 
and 40 µM C53 for 24 hours after which cover slips were probed with a KPNB1 antibody. 
Inverted Fluorescent Microscope was used to monitor KPNB1 fluorescence in the Cy3 
fluorescent channel and DAPI used for nuclear fluorescence. The results showed that without 
treatment, KPNB1 was present mostly in the nucleus for majority of the cells (Figure 4.4 A). 
In 20 µM C53 treated cells the localisation remained largely in the nuclear compartment 
(Figure 4.4 B). A notable increase in overall KPNB1 fluorescence was observed after 40 µM 
C53 treatment in comparison to the control cells.  
Quantification of the fluorescence across a cell using a representative immunofluorescent 
image of a single cell was performed with DAPI fluorescence indicating the nucleus. The 
fluorescence across the cell was quantified using the ImageJ software. The DAPI and Cy3 
(KPNB1) fluorescence intensity was then plotted and compared. Results show very similar 
fluorescent intensities and localisation patterns when comparing untreated (DMSO) to 20 µM 
C53 treatment (Figure 4.5 A and B). For cells treated with 40 µM C53, an increase in KPNB1 
fluorescence across both the cytoplasmic and nuclear compartments (overall) was observed  
(Figure 4.5 C). These results suggest that 40 µM C53 treatment may cause an elevation in 
KPNB1 expression. However, the results are not sufficiently conclusive evidence that C53 
affects the localisation of KPNB1. These experiments were also performed in CaSki cells, but 
the data was difficult to interpret likely due to the epithelial-like morphology which resulted 
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in cells being more compact and overlapping one another making it difficult to distinguish the 
















Figure 4.4 C53 had no effect on the localisation of KPNB1. HeLa cells were plated on cover 
slips flamed and treated with either DMSO or 20 µM and 40 µM C53 for 24 hours. Cells were 
probed with KPNB1 antibody and visualized by fluorescent microscopy to analyse localization 
of KPNB1 in the cell. (A) Localisation of KPNB1 is nuclear in control cells. (B) 20 µM C53 treated 
cells showed a nuclear localisation for KPNB1 while (C) 40 µM C53 showed an increase in 
KPNB1 fluorescence in both nuclear and cytoplasmic compartments. Experiments were 


























































Figure 4.5. C53 caused an increase in fluorescent intensity at highest dose. Cells were 
treated with C53 for 24 hours and probed with KPNB1 (Cy3) antibody and DAPI (nuclear stain). 
Images were captured using fluorescent microscopy and a representative image was used to 
quantify the KPNB1 (Cy3) and DAPI fluorescence intensity using ImageJ. DAPI fluorescence 
indicative of nuclear localisation. (A) Quantification of fluorescence for control cells shows an 
increase of KPNB1 in the nuclear compartment which is seen for (B) 20 µM C53 treatment 
too. (C) For 40 µM C53 treatment a substantial proportional increase in KPNB1 fluorescence 
is observed in both nuclear and cytoplasmic compartments. Experiments were performed two 
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4.2.5 Investigating the nuclear localisation of KPNB1 using nuclear/cytoplasmic 
fractionation. 
Immunofluorescent analysis of KPNB1 in response to C53 treatment suggested an increase in 
KPNB1 expression for 40 µM C53 but effects on nuclear localisation were not apparent. We 
therefore investigated the localisation of KPNB1 using nuclear cytoplasmic fractionation. 
Nuclear and cytoplasmic proteins were harvested from DMSO, 20 µM and 40 µM C53 treated 
cells for 48 hours.  This time point coincided with changes in cell proliferation.  
The levels of KPNB1 in the nuclear and cytoplasmic fractions was analysed by western blot. 
Little to no change in KPNB1 levels in the nuclear or cytoplasmic KPNB1 was detected for both 
20 µM and 40 µM treatment (Figure 4.6). Together these results suggest that C53 affects the 
nuclear presence of KPNB1 cargo proteins but has little/no effect on the subcellular 












































Figure 4.6. C53 lead to no change in localization in KPNB1. Western blot analysis of nuclear 
and cytoplasmic proteins from HeLa cells treated with C53 for 48 hours. Whole cell proteins 
(WC) served as a control of KPNB1 expression. GAPDH and Histone H3 were used as 
cytoplasmic and nuclear loading controls, respectively. Results showed no change in 
localisation or expression of KPNB1 after 48 hours of C53 treatment. Experiments were 
performed two independent times. 
WC Cyto Nuc 
KPNB1 
GAPDH 




































































The small molecule, C53 was identified for its potential to bind and inhibit KPNB1 function. 
Previously we investigated the effect of C53 on cancer cell biology. The effect of C53 
treatment on KPNB1 mediated nuclear import has not yet been investigated. Therefore, in 
this chapter we performed a preliminary investigation of the effect of C53 treatment on the 
import of known KPNB1 cargo proteins as well as the effect on KPNB1 localisation. 
We firstly investigated the effect of C53 on KPNB1 cargo protein import. Like INI43, a 
previously described KPNB1 inhibitor, C53 was shown to inhibit the import and activity of 
KPNB1 cargoes, NFAT and NF-ĸB [92]. As previously mentioned, NFAT and NF-ĸB were 
selected on the premises of being cargoes that are shuttled between the nucleus and 
cytoplasm in a KPNB1-dependent manner.  Next, we investigated the effect of C53 on KPNB1, 
its potential target. Our results showed that C53 had no effect on the subcellular localisation 
of KPNB1. Together these results show that C53 significantly inhibits the nuclear import of 
KPNB1 cargo proteins, however it does not affect the localisation of KPNB1. We speculate 
that C53 could interfere with the binding of cargoes however, it may not block the shuttling 
of KPNB1 between the nuclear and cytoplasmic compartments. Due to limited time, we were 
unable to test this hypothesis. Ideally, biophysical assays such as crystal structures of KPNB1 
bound to the small molecule is required. This forms part of future research in our laboratory 
which includes protein purification and crystallography. Crystal structures of KPNB1 protein 
in combination with KPNα and Ran have been solved. The unliganded crystal structure of 
human KPNB1 has not been solved yet. Therefore, compound binding studies are limited to 
computational docking [93].    
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There are very few small molecules identified to date that target KPNB1.The first small 
molecule inhibitor of KPNB1 identified was Karyostatin 1A. This compound was shown to 
inhibit KPNB1 mediated import. Through cargo studies, two cargos namely FITC-BSA-NLS as 
well as GFP-NFAT were shown to accumulate in the cytoplasm after treatment with 
Karyostatin 1A at concentrations of 10 µM and 25 µM respectively. Using docking studies as 
well as Surface Plasmon Resonance (SPR), to measure the interaction of the compound with 
KPNB1, Karyostatin 1A was shown to interfere with the Ran-GTP and KPNB1 interaction which 
in turn affected nuclear import. These results provided the first evidence of a potential small 
molecule inhibitor of nuclear import [59]. Karyostatin 1A off-target effects have however not 
yet been investigated. One of the commercially available inhibitors of KPNB1, Importazole has 
also been shown to bind KPNB1 through FRET-based studies. Like Karyostatin A1, Importazole 
was also shown to interfere with the RanGTP and KPNB1 interaction [60].  
More recently, research by Kim et al discovered an Aminothiazole derivative ((E)-N-(5-
benzylthiazol-2-yl)-3-(furan-2-yl) acrylamide) with anticancer properties. Through proteomic 
studies this aminothiazole derivative was shown to target KPNB1. The competitive binding 
assay further showed that the compound binds KPNB1 with a strong binding affinity  
(Kd = 20 nM) [94]. Further work by Siyoung et al. showed that the aminothiazole derivative 
binds on the concave surface of KPNB1 [95]. Crystal structures of KPNB1 with any of these 
compounds however are not available yet. 
Future work in our laboratory aims to purify KPNB1 and perform biophysical assays to 
investigate the binding of INI43 and C53 to KPNB1. The results in this chapter however 
provides evidence that small molecules like C53 affect the nuclear import of KPNB1 cargo 
proteins.  




CHARACTERISATION OF THE IN VITRO ADME 
PHARAMACOKINETICS AND IN VIVO TOXICOLOGY OF C53 
 
5.1 INTRODUCTION 
The drug discovery and development process involves the use of in vivo and in vitro 
experimental models. The different models ranging from cell culture to animal work, healthy 
humans and patients involved in clinical trials are used at different stages of drug discovery 
and development to determine the efficacy and safety of candidate drug-like compounds 
[88]. We have preliminary evidence that C53 has cancer cell killing effects using cell culture 
models. To add to the biological data generated for C53, we performed in vitro 
pharmacokinetic studies on C53. 
Pharmacokinetics refers to the study of the movement of a drug in the body which can be 
investigated through Absorption, Distribution, Metabolism and Excretion (ADME) studies. The 
ADME parameters can be tested in both in vivo and in vitro models. These parameters are 
extremely important in the prediction of drug behaviour in animal models or patients. In vitro 
ADME models involve the use of assays that give pharmacokinetic parameters such as plasma 
protein binding, solubility, permeability and metabolic stability. In vivo ADME models involve 
the use of animals or human subjects to provide information such as clearance, oral 
bioavailability, distribution and exposure of drugs [96]. These findings are critical to the future 
success of a compound as a treatment agent.  
Research has shown that many of the failures of drug candidates occurred due to poor 
pharmacokinetic properties e.g. poor absorption or excessive metabolism [57]. The early 
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screening of pharmacokinetic properties in the form of in vitro and in vivo ADME screens has 
significantly decreased the portion of failing drug candidates in clinical trials [36]. Therefore, 
this evidence shows the need of early pharmacokinetic screening of drug like compounds to 
improve the success of compounds that are tested further in living systems and clinical trials. 
This chapter is aimed at the early characterisation of the in vitro ADME pharmacokinetic 
properties of C53. In vitro assays included plasma protein binding, lipophilicity, kinetic 
solubility, permeability and metabolic stability which were done with assistance from H3D 
Africa, based at the University of Cape Town. In this chapter we also investigated the in vivo 
toxicology of C53 in a nude mouse model. 
5.1.1 Plasma protein binding 
Plasma protein binding refers to the extent which a drug binds to plasma protein. The 
increased importance of plasma protein binding lies in the fact that there is a high 
concentration of proteins in plasma of which numerous drugs bind. The percentage of drug 
binding can have implications on distribution which can be explained through the Free Drug 
Theory (FDT). The FDT states that in the absence of energy-dependent processes (pH gradient, 
uptake transporters) when steady state equilibrium is reached the percentage of free drug in 
the plasma is equal to the free drug in the tissue. The free drug is the unbound drug which is 
available to elicit the pharmacological activity (Figure 5.1). Hence, it is important to measure 
the extent of plasma protein binding which will also give information on the amount of free 
drug available to elicit the relevant pharmacological activity [97]. 
 
 




Figure 5.1: The free drug distribution, at equilibrium, between the blood plasma and tissue 
according to the Free Drug state theory. The amount of free drug in the blood plasma is 
equivalent to the free drug in the tissue [97]. 
 
Plasma protein binding influences the rate of diffusion between plasma and tissue therefore 
influencing the volume of drug distribution and the drug clearance.  It is usually desirable to 
avoid highly bound drugs as small changes in the plasma protein binding can lead to significant 
fluctuations in the free drug fraction. The reason the free drug fraction should not fluctuate 
dramatically is because fluctuation in the free drug may lead to toxic side effects which is 
more apparent in highly bound drugs in comparison to moderately bound drugs. However, 
there are commercially available effective anticancer drugs that have high protein binding 
e.g. Multi Kinase Inhibitor, Sorafenib has a protein binding of 97%; the EGFR-inhibitor, Gefinib 
has >97% binding and the tyrosine kinase inhibitor, Imatinib has a protein binding of >99%. 
This evidence shows that every drug acts uniquely and may still have good pharmacological 
activity despite high plasma protein binding [97]  
 




Lipophilicity refers to the ability of a compound to dissolve in fats, lipids or non-polar solvents 
such as hexane. In ADME studies, a calculated partition coefficient (LogD) is routinely used to 
analyse lipophilicity in vitro which is representative of the molecular desolvation of a 
compound from aqueous phase to cell membranes and protein binding sites. Lipophilicity is 
an important ADME parameter as it contributes to a compounds solubility, permeability, 
potency and metabolism in a living system. Highly lipophilic compounds frequently lead to 
rapid metabolism, low solubility and poor absorption. Similarly, low lipophilicity leads to poor 
ADME properties [98]. The optimum range of lipophilicity has been reported to be within a 
LogD range of 1 and 3 which ensures optimal physiochemical properties [99]   
5.1.3 Solubility 
Solubility is defined as the concentration of the compound before the appearance of a 
precipitate. This parameter is important for drugs that are administered orally. It has been 
established that the solubility, dissolution and gastrointestinal (GI) permeability are 
fundamental properties which control the extent of drug absorptions and bioavailability 
[100]. In drug discovery, the amount of insoluble drug candidates has increased over the years 
with almost 70% of new drug candidates being water insoluble. Therefore, there is a growing 
need for identifying drug candidates that are water soluble to avoid drug like compounds 
from precipitating out and causing toxic side effects [100]. 
5.1.4 Permeability 
Due to the ease of this route of administration, the major goal of drug development currently 
is to develop drugs which can be administered orally. For a drug to reach the systematic 
circulation it must first pass through the intestinal membranes via passive diffusion, assisted 
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transport or active transport. A correlation between the intestinal absorption and the 
intestinal permeability for a drug has been reported [101]. Therefore, the permeability value 
of a compound is an important index of its human intestinal absorption. There are several in 
vitro models used to measure passive permeability such as Parallel Artificial Membrane 
Permeability Assay (PAMPA), the human colon adenocarcinoma (Caco-2) cell lines and the 
Madin-Darby canine Kidney (MDCK) cells. The aim of these in vitro assays is to predict the 
apparent permeability (LogPapp) of a drug-like compound where a LogPapp >-5 is characterised 
as high permeability while a LogPapp <-5 is characterised as low permeability [101].  
5.1.5 Metabolic stability  
Metabolic stability refers to the biotransformation of a compound over time. Metabolic 
stability studies represent some of the earliest studies used by pharmaceutical companies to 
predict in vivo pharmacokinetics. The importance of in vitro metabolic stability studies is the 
relation to the metabolic clearance in vivo. The metabolic stability in vivo has a relationship 
to the half-life and bioavailability of a compound. Therefore, in vitro metabolic stability 
studies are an important indicator of clearance in a living system. The in vitro metabolic liver 
systems are believed to reflect the hepatic clearance in vivo [102]. The hepatic clearance is 
the  
first-pass elimination of a drug where a compound is metabolized by enzymes found in the 
liver. Subcellular fractions known as liver microsomes or S9 fractions are used to measure the 
rate of disappearance of a drug within a period which would be representative of the half- 
life and clearance of the drug. Metabolic stability is thus of importance to predict how quickly 
a drug is cleared in the system, which would have implications on the dosage and 
bioavailability of a drug [102]. 
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In this chapter, the above ADME assays will be used to evaluate the in vitro pharmacokinetic 
properties of C53. The results of these assays serve as indicators of how well the compound 
(C53) will be absorbed, distributed, metabolized and excreted in a living system.  
5.1.6 In vivo toxicology study of novel compound  
Toxicity refers to any adverse effects shown by a substance after administration. Toxicity 
testing of new compounds is essential in drug discovery and development. The toxicity of a 
substance can be tested in vitro and in vivo. Repeated dose toxicity testing refers to a test 
carried out for a minimum duration of 28 days with the substance being administered 
repeatedly. Usually in in vivo animal models, rodents of any gender and age 5-6 weeks are 
used. At the end of the study, tissue from various organs are removed and tested by weight 
or histology changes [103]. Since C53 is a novel compound that has not been previously 
tested, in this chapter we also tested the repeated dose toxicity of C53 in nude mice for a 
duration of 28 days. The toxicity will be investigated at three different concentrations of C53 
to identify whether C53 is tolerable in a mouse model and if so which concentration is the 
most tolerable. These results will provide important information of the toxicity of C53 and the 
concentration of C53 that can be tolerated. This tolerable C53 concentration will be used in 









PART I: INVESTIGATING THE IN VITRO ADME PHARAMACOKINETICS OF C53 
5.2.1 Investigating the plasma protein binding of C53 using human plasma   
To evaluate the protein binding of C53, a plasma protein binding assay was performed using 
human blood plasma. The protein binding assay is used to evaluate how much of the drug is 
bound to the proteins found in blood plasma. The binding potential of a compound has major 
implications on its distribution, toxicity and pharmacological activity. For most drugs, the 
clinical response is dependent on the free (unbound) drug concentration [105]. 
In this assay, C53 was incubated in 1 µM human plasma for 30 minutes at 37˚C to allow plasma 
protein binding before ultracentrifugation for 4 hours to allow for the separation of the bound 
drug from the free drug. All samples including controls were then filtered and supernatant 
submitted for LC-MS/MS analysis. The results of the protein binding of C53 shows that C53 
has a protein binding of 90.3% with the fraction of free drug being 0.09 (Table 5.2). These 
results suggest that C53 has moderate protein binding.  
 
Table 5.2. Plasma protein binding results for C53 incubated in human plasma. Fu  
(free fraction) shows free drug. Controls used were Warfarin (high binding) and Caffeine  
(low binding). Experiment performed in duplicates. 
Compound % Protein Binding Fu % Degradation 







5.2.2 Investigating the Kinetic solubility of C53 in PBS (pH 7.4) 
 Kinetic solubility refers to the concentration of the compound in solution before some 
precipitate forms. The ability for a compound to be highly soluble in an aqueous media is 
important for oral absorption. [100].  
The Kinetic solubility of C53 was measured using a shake flask method where a 10 mM stock 
of C53 in DMSO was used to prepare calibration standards (10-220 µM) and spike (1:50) 
aqueous samples of PBS with a final DMSO concentration of 2%. After shaking, samples were 
filtered and analysed by High Pressure Liquid Chromatography (HPLC). The calibration 
standards were used to construct a best fit calibration curve which was used to determine 
the aqueous solubility of C53. The kinetic solubility was ranked based on a 200 µM 
preparation in 2% DMSO (Table 5.3). 
Table 5.3. Solubility ranking based on a 200 µM preparation in 2 % DMSO. 
Solubility Class Concentration (µM) 
High ≥ 150 
Moderate 50-150
Low 5-49
Very Low ≤ 5 
96 
The results for the kinetic solubility of C53 showed that it has moderate kinetic solubility with 
a kinetic solubility of 100 µM (Table 5.4). This result suggests that C53 is readily soluble and 
should not precipitate out in the circulatory system. 
Table 5.4. The kinetic solubility results of C53 in PBS (pH 7.4). 
Compound pH 7.4 Solubility (µM) 
C53 100 
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5.2.3 Investigating the lipophilicity of C53 
In order to investigate the lipophilicity of C53 a miniature shake flask method was used. The 
shake flask method was adapted to a microtiter plate where 495 µl of octanol was added to 
10 µl of C53 (10 mM in DMSO) followed by 495 µL phosphate buffer (0.1 M). The microtiter 
plate was then mixed to allow for distribution of test compound in the various layers. After 
mixing, the microtiter plate was centrifuged for 2 hours to allow for the complete separation 
of the two solvent layers. An aliquot of each phase (Octanol/PBS) was analysed by HPLC to 
determine the concentration of C53 in each phase. The partition coefficient was then 
calculated using the LogD calculation (Figure 5.2). The optimal LogD value of a compound is 
between 1 and 3.  
 
 
LogD7.4 = Log10    peak area octanol phase / octanol phase inj. volume 
                                    peak area buffer phase/ buffer phase inj. volume 
 
Figure 5.2. The LogD7.4 calculation used to calculate the partition factor for C53. 
 
The results for C53 show that the partition coefficient of C53 is 2 which is within the optimum 
range of LogD values (Table 5.4). Drug properties are ranked based on the LogD values  
(Table 5.5). According to the drug properties, C53 has moderate solubility and permeability 
as well as slow metabolism. This may suggest that C53 is favourable for oral absorption 
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Table 5.5. Impact of LogD7.4 on the drug like properties and possible in vivo impact [104]. 
Log D7.4 Common Impact of  
Drug-like Properties 
Common Impact in vivo 
< 1 Solubility high 
Volume of distribution low 
Permeability low 
Metabolism slow 
Volume of distribution low. 
Oral absorption blood brain 
barrier (BBB) penetration 
unfavourable. 
Renal clearance may be high 
1-3 Solubility moderate 
Permeability moderate 
Metabolism slow 
Balanced volume of 
distribution. Oral absorption 
and BBB penetration 
favourable. 
Renal clearance may be 
high. 
3-5 Solubility low 
Permeability high 
Metabolism moderate to 
high 
Oral bioavailability 
moderate to low. 
Oral absorption variable. 
>5 Solubility low 
Permeability high 
Metabolism high 
High volume of distribution 
(especially amines). 
Oral absorption 









   
99 
 
5.2.4 Investigating the apparent permeability of C53 
The main pharmacokinetic parameters for oral absorption of drugs is permeability and 
solubility. For a drug to enter the circulatory system and get to its target site it needs to pass 
through several membranes [101]. PAMPA is an in vitro assay which mimics the passive, trans-
cellular permeability of a drug like compound being screened for their oral absorption 
potential.  
To screen C53 permeability, a 96-well Multiscreen Filter plate was used. The membrane filters 
were pre-coated with hexadecane and allowed to dry before commencing with the assay. The 
hexadecane acts as an artificial lipid membrane which the drug would be required to pass 
through in a similar manner to the passive diffusion in vivo. Phosphate buffer was added to 
the 96 well acceptor plate. Donor buffer was spiked with C53 (1 µg/ml) before the donor plate 
was slotted into the acceptor plate forming a sandwich like arrangement. The plates were 
then incubated with gentle shaking to allow diffusion of C53 to take place. Samples from the 
acceptor plate were then prepped and analysed by LC-MS/MS to determine the apparent 
permeability (LogPapp).  
Results from the PAMPA assay show that C53 has an apparent permeability of -4.3 which is 
categorized as a high permeability value (Table 5.6). This result shows that C53 would be 
readily absorbed in a living system and making it ideal for oral absorption. 
 
Table 5.6. Permeability (PAMPA) results for C53 at pH 6.5 
Compound LogPapp (pH 6.5) Classification 
C53 -4.3 High 
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5.2.5 Investigating the hepatic metabolic stability of C53 using liver microsomes  
To investigate the hepatic metabolic stability of C53, liver microsomes were used. Metabolic 
stability was investigated by incubating 1 µM C53 in mouse, rat or pooled human liver 
microsomes (0.4 mg/ml) at 37˚C at specific time points in the presence or absence of NADPH. 
NADPH is a cofactor which is required for the initiation of the enzymic reaction. At specific 
time points reactions were quenched before analysing supernatant by LC-MS/MS. Metabolite 
searches were not conducted during this assay. The microsomal stability results (Table 5.7) 
for C53 show the half-life to be 7.2, 4.3 and 4.2 minutes in human, rat and mouse microsomes, 
respectively. The predicted clearance for all the microsomes was > 250 ml/min/kg which 
suggests that 250 mL of C53 would be cleared per minute based on the mass of the respective 
animal. Based on these results, it can be predicted that C53 would have a short half-life and 
rapid clearance in vivo. 
 
Table 5.7. Metabolic stability data of C53 in pooled human, rat and mouse liver microsomes. 
Predicted in vivo clearance shown in the last column. 
 Liver microsomes Half-life (min) Predicted in vivo 
Clearance 
(mL/min/kg) 
C53 Human 7.2 >250 
Rat 4.3 >250 
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PART II: C53 IN VIVO TOXIOCOLOGY STUDIES 
5.2.6 Investigating the toxicology of C53 in vivo  
Toxicity testing of a new compound is essential in drug development. Toxic side effects like 
those seen for Leptomycin B, are a major reason for drugs not being developed further or 
being discontinued [105]. Having established that C53 has tolerable ADME pharmacokinetic 
properties we next investigated the toxicity of C53. 
Here we examined the possible toxic side effects of C53 by performing a repeated dose 
toxicity analysis. C53 was administered interperitoneally twice a week for a period of 28 
days. The mice body mass was measured 4 times a week and welfare monitoring of each 
mouse was performed daily. In the experiment, treatment mice were treated with C53  
(10 µg/g, 30 µg/g or 50 µg/g) and control mice received 7.5% DMSO in PBS. Throughout the 
experimental duration no signs of distress or pain were observed with the animals. Results 
for all the drug concentrations show a body mass fluctuation similar to that of the control 
(Figure 5.3 A-C). The gain in body mass at the end of the study, which is represented by a 
box-and-whisker, shows a significant increase in the body mass gain for 10 µg/g and 30 µg/g 
C53 treatment compared to the control group of mice while the 50 µg/g C53 group showed 
no significant change compared to the control group (Figure 5.4). Factors that can affect 
weight gain include food and water consumption. A possible explanation for why the 10 
µg/g and 30 µg/g treated mice gained more weight could be due to more consumption 
compared to control group which is a factor that causes variability in body mass. Hence, 
body mass was not the only parameter used for assessment of animal welfare and C53 
toxicology (liver mass and autopsie).  The body mass recordings as well as the body mass 
gain at the end of the study show that C53 is tolerable in nude mice. 




Figure 5.3. Toxicology analysis of C53. The repeated dose toxicology study was carried out 
using three different concentrations of C53 (10 µg/g, 30 µg/g or 50 µg/g). Body mass was 
measured the first day of treatment, and 4 times a week thereafter. Body mass was calculated 
as a percentage increase from the first day measurement for (A) 10 µg/g, (B) 30 µg/g and  































































































Figure 5.4. Gain in body mass on final day. The repeated dose toxicology study was carried 
out using three different concentrations of C53 (10 µg/g, 30 µg/g or 50 µg/g). Body mass was 
measured the first day of treatment, and 4 times a week thereafter. Body mass was calculated 
as a percentage increase from the first day measurement for 10 µg/g. Box and whisker 
represents the gain in body mass at the end of the study for each group (n=6). Results shown 











































To further validate that C53 did not cause internal toxic effects, after mice were sacrificed a 
post-mortem evaluation of each mouse was performed by an animal technician. Post-mortem 
evaluation of the C53 treated mice versus the control mice concluded no abnormalities e.g 
discolouration or inflammation, was observed in the spleen, liver, heart, ovaries and kidney. 
There was no difference in the appearance of the internal organs of the control mice 
compared to the C53 treated mice (Figure 5.5 A). Since the liver is responsible for the first 
pass of drug metabolism, research has reported an enlarged liver as a sign of toxicity [106]. 
We therefore measured the liver mass of the control and C53 treated mice at the end of the 
study, and normalised it relative to their body mass. Results of the relative liver mass showed 
no significant difference in the liver masses of the control group versus the C53 treated mice 
for all C53 concentrations (Figure 5.5 B).  Together these results suggest that C53 is tolerable 
up to, but not restricted to 50 µg/g. 
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Figure 5.5. Post-mortem evaluation and liver size measurement at the end of toxicology 
study. (A) Post-mortem evaluation on each mouse for each group of C53 treated and control 
treated mice were evaluated and showed no toxic side effects in the internal organs. (B) At 
the end of the study mice’s liver was removed and measured then normalised to their body 
mass. Bar graph represents the relative liver mass for each group which showed no significant 
difference (n=6 per group). 























In this chapter, we describe the in vitro pharmacokinetic properties and the in vivo toxicology 
study for C53. This is the first study to describe the pharmacokinetic properties of the 
pyrrolidine derivative, C53 (1-benzyl-4 [(4methoxy-1-naphyl) methylamino]-N-methyl-
pyrrolidinecarboxamide). Pharmacokinetic properties of several anticancer drugs have been 
investigated in vitro and in vivo for preclinical studies. These drugs include Imatinib, Gefitinib 
and Sorafenib which are all commercially available small molecule inhibitors used in cancer 
therapy [105].  
The main purpose of pharmacokinetics is to investigate the bodily absorption, distribution, 
metabolism and excretion of drugs. When a drug is administered orally the first process that 
takes place is absorption. Drugs administered orally are absorbed by the stomach and small 
intestine. Next the drug passes through the liver then enters the circulatory system. For the 
drug to reach its target site it needs to be transported. This occurs through a process known 
as distribution. Once a drug is distributed throughout the body, it is broken down in a process 
known as metabolism. This usually occurs in the liver where specific liver enzymes are 
responsible for the biotransformation of parent drugs into metabolites. The metabolites 
usually have no effect and are easily excreted however in other drugs the metabolites are 
pharmacologically active. The final process is excretion. This is when the drug is eliminated 
from the body primarily through faeces or urine [107]. 
We investigated the ADME pharmacokinetic properties of C53 using five assays namely 
plasma protein binding, lipophilicity assay, kinetic solubility, permeability assay and the 
metabolic stability assay. Results showed that C53 has moderate protein binding and 
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solubility. Further results showed that C53 has high permeability and optimum lipophilicity 
while metabolic studies showed that C53 has a short half-life and predicted rapid clearance.   
The plasma protein binding of C53 was shown to be 90.3% meaning majority of the compound 
is bound to the plasma protein. High plasma protein binding is unfavourable however, 
literature has shown a few commercially available anticancer drugs that have high plasma 
protein binding. For example, Imatinib (Gleevec) has a plasma protein binding of 95% and is 
predominantly bound to albumin and α-glycoprotein. While the anticancer drugs Gefinitib 
and Sorafenib have plasma protein binding of 90% and 99.5%, respectively [108-110]. This 
evidence shows that a moderate to high plasma protein binding does not necessarily relate 
to the effectiveness of an agent. 
The lipophilicity of C53 was defined as a partition coefficient. Results showed that the 
partition coefficient (LogD) for C53 was within the optimal range. This result also has specific 
implications for C53 in vivo. According to the drug property rankings by Edward KH et al. a 
LogD value between 1 and 3 would suggest that C53 is favourable for oral absorption and 
penetration of the blood brain barrier however, rapid clearance in vivo may be expected 
[104]. Positively, C53 showed good solubility and permeability which suggests that the 
compound has ideal oral absorption properties. 
Metabolic studies of C53 using liver microsomes showed that C53 has a short half-life 
therefore is expected to clear rapidly in vivo which is not ideal. Research by Masimirembwa 
and co-workers previously showed several compounds which where metabolically unstable 
in vitro however, showed low clearance in vivo [102]. This was surprising as the metabolic 
stability in vitro usually acts as an indicator for the metabolic clearance in vivo. The reason for 
this observation is that the liver microsomes provide an artificial availability of compound to 
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the enzymes that, due to protein binding and permeability, does not occur in vivo. This would 
explain the differences in the data obtained in the in vitro metabolic studies versus the in vivo 
metabolic studies of the compounds investigated by Masimirembwa and co-workers [102]. 
Therefore, the liver microsomes may not be a conclusive indication of how a compound will 
act in vivo but merely acts as a possible indicator. This illustrates the importance of evaluating 
whether the in vitro metabolic stability data correlates with the in vivo metabolic stability 
data. 
Interestingly, research has shown anticancer compounds where the half-life of the parent 
compound is shorter than that of the active metabolite. This was the case for Gleevec, a 
commercially available tyrosine kinase inhibitor. Gleevec showed an elimination half-life of 
18 hours but when a metabolic identity (MetID) study was performed a pharmacologically 
active metabolite of Gleevec (CGP74588) was discovered and this metabolite showed an 
elimination half-life of 40 hours [108]. Therefore, further studies in the form of MetID may 
identify possible metabolites of C53 which may be pharmacologically active and have a longer 
half-life. 
Having established the ADME pharmacokinetic properties for C53, next we investigated the 
toxicology of C53 in vivo through a repeated dose toxicology study. Results of the toxicology 
study showed C53 being tolerable up to but not restricted to 50 µg/g. Post mortem evaluation 
of mice treated with C53 showed no toxic effects and relative liver mass was not significantly 
different between control treated and C53 treated mice groups. These results suggest that 
C53 is tolerable in vivo, showing no toxic effects.  
In summary, this chapter shows that C53 has moderate solubility and lipophilicity as well as 
high permeability in vitro. C53 also showed moderate plasma protein binding and in vitro 
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metabolic studies showed short half-life in liver microsomes. This data suggests that C53 has 
ideal characteristics for oral absorption however, further work in the form of metabolite 
identification (MetID) may be required to identify metabolites with longer half-life and 
pharmacologically active. In vivo toxicology studies showed that C53 is tolerable in nude mice 
showing no toxic effects externally or internally in all mice groups. This result suggests that 
C53 is tolerable in vivo.  
Future work in our lab aims to investigate the in vivo ADME pharmacokinetics of C53 and 
monitor its effect on tumour development using a mouse xenograft model for cervical and 


















Karyopherin proteins are soluble nuclear import or export proteins which are responsible for 
the shuttling of cargo in and out of the nucleus [31]. The most well characterised Karyopherin 
is CRM1 which is a nuclear export protein. CRM1 has been shown to be overexpressed in 
several malignancies and has been shown to be a potential target for anticancer therapeutics 
[17,35-36]. Many inhibitors of CRM1 e.g. the SINE’s have been developed and are being tested 
in clinical trials [111]. With most research focusing on the nuclear export pathway, very little 
is known about targeting nuclear import as an anticancer target. Like CRM1, there is growing 
evidence that the Karyopherin import protein KPNB1 is overexpressed in different cancers 
[17,44]. The silencing of KPNB1 lead to cell death through apoptosis in cancer cells with little 
effect on non-cancer cells [17]. This evidence suggests that KPNB1 has potential as a 
druggable candidate like that of CRM1. 
In this study, we investigated a novel small molecule inhibitor, C53 which was selected from 
in silico docking studies as a potential inhibitor of nuclear import that associates with KPNB1. 
We investigated the effect of C53 on cancer cell biology, the effect of C53 on KPNB1 cargo 
proteins as well as characterised the in vitro ADME pharmacokinetic properties of C53.  The 
in vivo toxicology of C53 was also investigated using a nude mouse model in order to 
investigate whether the compound is tolerable in a living system.  
We report that the cancer cell lines tested in our study appeared more sensitive to C53 with 
EC50 values of C53 in cervical and oesophageal cancer cell lines which were 1.5 – 2 fold lower 
than that of non-cancer cells tested. This sensitivity was validated in cell proliferation studies 
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where concentrations of 10 µM and 20 µM C53 significantly reduced the cell proliferation of 
cervical cancer cell lines but had little effect on the non-cancer fibroblast cells, FG0. The 
reduction in proliferation was shown to be associated with a G1/S cell cycle delay. The cell 
cycle delay triggered by C53 treatment also resulted in a decrease in the levels of cell cycle 
associated proteins, CyclinD1 and CDK4 which are essential proteins for the regulation of the 
G1 phase of the cell cycle [80]. C53 treatment also induced cell death by apoptosis similar to 
that described after treatment with another small molecule, INI43 or silencing of KPNB1 with 
siRNA in cervical cancer cell lines [40,62]. Earlier studies suggest that cancer cells may have 
increased reliance on KPNB1 hence their increased sensitivity when nuclear import pathways 
are inhibited. 
Crystal structures of KPNB1 have been determined however, the unliganded human KPNB1 
crystal structure has not yet solved. Therefore, ligand binding studies with KPNB1 are limited 
to molecular docking at present [93]. Like INI43, C53 was selected from an in silico docking 
study that identified compounds which potentially bound KPNB1. Other than docking studies, 
the inhibitory potential of C53 for KPNB1 has not been investigated to date. In the absence of 
X-ray crystal data of KPNB1:small molecule interaction, we  investigated the effect of C53 
treatment on the nuclear import of KPNB1 cargo proteins as well as KPNB1 localisation as 
preliminary evidence that C53 targets the nuclear import pathway. Our study shows that C53 
inhibited the nuclear import of KPNB1 cargo proteins slightly however, had no effect on 
KPNB1 localisation. The inhibition of KPNB1 cargoes by C53 was found to be similar to that 
described for INI43 and Importazole [62]. This study provides evidence that C53 inhibits 
KPNB1 cargo proteins however further binding studies in the form of biophysical assays are 
required to confirm whether C53 binds KPNB1 directly. While molecular docking studies are 
an indication of possible binding of ligands/compounds to a protein of interest, purified 
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KPNB1 is required to perform biophysical analysis of KPNB1:C53 interaction. Protein 
purification and biophysical analysis was outside the scope and timeframe of this MSc project 
and forms the basis of ongoing research in our laboratory. 
With many anticancer agents failing in clinical studies due to unfavourable pharmacokinetics 
or toxicity, there lies a lot of importance in testing possible drug-like compounds for their 
pharmacokinetic properties early in the drug development process [60]. A well-known natural 
compound Leptomycin B, an inhibitor of CRM1 showed great potential as a SINE however due 
to toxic side effects in clinical trials this compound was discontinued [80]. We therefore, 
investigated the pharmacokinetic properties of C53 to investigate whether it would be 
tolerable in a living system.  
Our data provided evidence for C53 as a potential anticancer compound using in vitro models 
however, in vivo studies provide a realistic model of the tumour microenvironment. Before a 
compound enters a living system, it is important to have predictive data which could possibly 
indicate whether it will be tolerable in in vivo models. To have a better understanding of how 
C53 may behave in a living system we performed in vitro ADME studies. These studies, 
included five assays which predicted the solubility, lipophilicity, permeability, plasma protein 
binding and the metabolic stability of C53. The ADME in vitro results revealed that C53 had 
moderate plasma protein binding and solubility. The lipophilicity was shown to be ideal while 
the permeability was categorized as high. Metabolic studies revealed that C53 has a low half- 
life which may suggest rapid intrinsic clearance in vivo. These findings suggest that C53 is 
readily soluble and is ideal for oral absorption however, a short half-life may result in rapid 
clearance. It should however, be noted that in vitro metabolic studies may not necessarily be 
a conclusive indication of what may occur in vivo as several compounds have been shown to 
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have short half-life in vitro but not in vivo [102]. The short half- life observed for C53 could be 
due to a metabolite formation. Since the liver is responsible for the metabolic break down of 
parent compounds, the products formed (metabolites) after the enzymic reactions may be 
pharmacologically active and have longer half-lives as observed for Gleevec, a commercial 
tyrosine inhibitor with anticancer activity [108]. Therefore, the investigation into the 
metabolites possibly formed by C53 metabolic break down may lead to the discovery of 
pharmacologically active metabolites of C53 which may potentially have longer half-lives.  
With C53 showing promising ADME pharmacokinetic properties we next investigated 
whether C53 is tolerated in an in vivo mouse model. The rationale for this was to determine 
whether C53 was firstly tolerable in a living system and if so at what concentration. The in 
vivo toxicology study was performed as a pilot for the identification of the drug concentration 
of C53 to be used in future xenograft studies. The results showed that all the drug 
concentrations were tolerable as all the mice gained weight in comparison to the control 
group. Post mortem evaluation showed no toxic effects internally and relative liver masses of 
C53 treated mice versus control group mice was not significantly different. Together these 
results show that C53 is tolerable in vivo. 
In summary, results presented in this dissertation provide evidence that the novel small 
molecule inhibitor, C53 has anticancer effects in vitro and significantly inhibits nuclear import 
of KPNB1 cargoes. Furthermore, ADME experiments show that C53 has properties ideal for 
oral absorption but may have rapid clearance in vivo as shown by metabolic studies. In vivo 
toxicology studies provide evidence that C53 is tolerable in a nude mouse model. We propose 
that in vivo ADME pharmacokinetics studies on C53 be done to investigate whether in vitro 
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ADME results correlate with in vivo ADME results. The in vivo efficacy of C53 as a small 




















6.1 Limitations and future recommendations 
1) In this study, we tested the effects of C53 on the proliferation on multiple cancer cell
lines, however the effect of C53 on nuclear import of KPNB1 cargo proteins and KPNB1
localization was confirmed using HeLa cells only. Attempts of showing this in CaSki
cells had limited success. Despite the optimization of transfection conditions using
various transfection agents, CaSki cells showed poor transfection efficiency therefore
could not be investigated for the effects of KPNB1 cargo protein import after C53
treatment. Difficulty with CaSki cells was also found in immunofluorescence analysis
as the morphology of these is more epithelial-like cells with compact and overlapping
packing making quantification of immunofluorescence data difficult. A
recommendation for future studies include testing the effects of C53 on nuclear
import on other cervical cancer cell lines.
2) While NFAT and NF-ĸB reporter assay results showed that C53 significantly reduces
nuclear import and activity of these KPNB1 cargo transcription factors, this data does
not confirm that C53 binds and inhibits KPNB1 directly. Future work will include the
use of biophysical assays to confirm direct binding of C53 on KPNB1. This will involve
the purification of KPNB1 for its use in protein:drug interaction studies such as circular
dichroism, Isothermal Calorimetry and X-ray Crystallography.
3) The ADME in vitro results suggest that C53 is ideal for oral absorption but has a short
half-life. Future studies could include investigating the metabolites of C53 and
determining their half-life.  In vivo toxicology studies showed that C53 is tolerable in a
mouse model therefore in vivo ADME will be performed in the future to investigate
the behaviour of C53 in a living system to evaluate whether the in vitro and in vivo
ADME results correlate.
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Cell culture solutions 
Trypsin-EDTA 
0.5 g Trypsin 
1.45 g Na2HPO4.2H20 
8 g NaCl 
0.2 g KHPO4 
0.2 g KCL 
10 mM EDTA, pH 8 
Make up to 1L with PBS 
 
Cell- freezing Media 
90 % Complete Media 
10 % DMSO 
 
MTT reagent (5 mg/ml) 
100 mg MTT 
20 ml PBS 
Vortex and incubate in water bath at 37˚C for 15 minutes 
Filter sterilize through 0.22 µm filter 
Store at 4˚C in the dark for a maximum period of a month 
 
Solubilisation Reagent 
25 g SLS in 250 mL dH20 
76.6 µl concentrated HCl 
 
 
Protein solutions  
 
RIPA buffer 
150 mM NaCl 
1% Triton-X-100 
1% Sodium Deoxycholate 
0.1% SDS 
10 mM Tris-CL pH 7.5 
Store in fridge 
 
PBS (10X) 
40 g NaCl 
1 g KCl 
3.82 g Na2HPO4.2H20 
1 g KH2PO4 
Make up to 500 ml with dH20 
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1M Tris (pH 6.8) 
24.23 g Tris 
200 ml dH2O 
Adjust pH with concentrated HCl to pH 6.8 
Make up to 200 ml with dH2O 
 
1 M Tris (pH 8.8)  
24.23 g Tris 
200 ml dH2O 
Adjust pH with concentrated HCl to pH 8.8 
Make up to 200 ml with dH2O 
 
Western blot solutions  
 
4% Stacking Gel 
3.65 ml dH20 
0.625 ml Tris (pH 6.8) 
50 µl 10% SDS 
0.650 ml 30% Acrylamide  
60 µl 10% APS 
6 µl TEMED 
 
10% Separating Gel 
2.75 ml dH20 
3.75 ml 1 M Tris (pH 8.8) 
100 µl 10% SDS 
3.35 ml 30 % Acrylamide  
200 µl 10% APS  
20 µl TEMED 
 
15% Separating Gel  
3.3 ml dH20 
3.9 ml 1 M Tris (pH 8.8) 
150 µl 10% SDS 
7.5 ml 30% Acrylamide  
150 µl 10% APS 
 15 µl TEMED 
 
Loading dye (6X) 
0.8 ml Glycerol 
0.1 ml Bromophenol Blue 
0.5 ml Tris pH 6.8 
0.6 ml 20 % SDS 
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10 X Running Buffer 
20 g Glycine 
31.6 g Tris 
50 ml 10% SDS 
Up to 500 ml with dH2O 
 
1 X Running Buffer 
100 ml 10 X running buffer 
900 ml dH2O 
 
10 X Transfer Buffer 
72 g Glycine 
19 g Tris 
Up to 500 mL with dH2O 
 
1 X Transfer Buffer 
200 ml Isopropanol 
100 ml 10 X Transfer 
700 ml dH20 
 
10 X TBS 
24.23 g Tris 
80.06 g NaCL 
Add 800 ml dH2O 
pH with concentrated HCl to pH 7.6 
Volume made up to 1 L dH2O 
 
1 X TBST 
100 ml 10 X TBS 
900 ml dH2O 
1 ml Tween-20 
 
5% milk powder 
1 g milk 
20 ml TBST 
 
 
Nuclear/ Cytoplasmic fractionation solutions  
 
Harvest Buffer (10 ml) 
100 µl 1M HEPES pH 7.9 
0.5 ml 1 M NaCl 
2 µl 500 mM EDTA 
50 µl Triton-X-100 




Buffer A (10 ml) 
100 µl 1 M HEPES pH 7.9 
100 µl 1 M KCl 
2 µL 500 mM 
2 µL 500 mM 
Up to 10 ml with dH20  
Buffer C (10 ml) 
10 µl 1 M HEPES pH 7.9 
0.5 µl 1 M NaCl  
1 µl 100 mM EDTA 
1 µl 100 mM EGTA 
20 µl 5% NP-40 
Up to 10 ml with dH20 
Cell cycle solutions 
5M NaCl 
58.44 g NaCl 
200 ml dH20 
0.1M PIPES 
3.02 g PIPES  
100 ml dH20  
Adjust pH to 6.8 
FACS staining solution 
5 µl Triton-X-100 
10 µl 1M MgCL2 
100 µl 5M NaCl 
500 µl 0.1 M PIPES (pH 6.8) 
5 µL Propodium Iodide (1 mg/mL) 
4335 µl dH20 
Immunofluorescence solutions 
4% Paraformaldehyde  
40 g paraformaldehyde  
900 ml PBS  
Heat to approximately 60˚C with constant stirring  
Raise pH by adding 1 M NaOH, until solution clears 
Make to 1 L with PBS  
Store at 4˚C 
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Mowiol Mounting Solution  
2.4 g Mowiol-488 6 g Glycerol  
6 ml dH2O  
Stir vigorously  
12 ml 200 mM Tris-Cl, pH 8.5  
Heat to 60˚C with stirring for 10 minutes  
Remove undissolved particles by centrifugation for 15 minutes 




1 M HEPES  
238.80 g HEPES  
800 ml dH2O  
Adjust to desired pH  
Make up to 1 L with dH2O  
 
0.5 M EDTA  
186.12 g Na2EDTA-2H2O 
 800 ml dH2O  
Adjust to pH 8.0 with NaOH  
Up to 1 L with dH2O 
 
0.5 M EGTA  
190.18 g EGTA  
800 ml dH2O  
Adjust to pH 8.0 with NaOH  













APPENDIX II- PROTEIN MARKER 
Figure AII. Protein molecular weight marker: Colour Prestained Protein Standard. Ladder 
used to determine the molecular weight of proteins subjected to polyacrylamide gel 
electrophoresis on 10-15% SDS-PAGE gels 
